

GRANT NUMBER DAMD17-98-1-8134

TITLE: Using Genetic Means to Identify Factors that Affect  
Estrogen Receptor Function

PRINCIPAL INVESTIGATOR: Roland Knoblauch

CONTRACTING ORGANIZATION: New York University Medical Center  
New York, New York 10016

REPORT DATE: July 1999

TYPE OF REPORT: Annual

PREPARED FOR: Commanding General  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
<small>Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.</small>				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 1999		3. REPORT TYPE AND DATES COVERED Annual (1 Jul 98 - 30 Jun 99)
4. TITLE AND SUBTITLE Using Genetic Means to Identify Factors that Affect Estrogen Receptor Function				5. FUNDING NUMBERS DAMD17-98-1-8134
6. AUTHOR(S) Roland Knoblauch				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) New York University Medical Center New York, New York 10016				8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING / MONITORING AGENCY REPORT NUMBER
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 words) <p>The mechanism of signal transduction by the estrogen receptor (ER) is complex and not fully understood. In the absence of estradiol, ER, like other steroid receptors, is complexed with Hsp90 and other molecular chaperone components, including an immunophilin, and p23. This Hsp90-based chaperone complex is thought to repress ER's transcriptional regulatory activities while maintaining the receptor in a conformation that is competent for high affinity steroid binding. However, a role for p23 in ER signal transduction has not been demonstrated. Using a mutant ER (G400V) with decreased hormone binding capacity as a substrate in a dosage suppression screen in yeast (<i>S. cerevisiae</i>), we identified the yeast homologue of the human p23 protein (yhp23) as a positive regulator of ER function. Overexpression of yhp23 in yeast increases ER transcriptional activation by increasing estradiol binding <i>in vivo</i>. Using a yhp23-GFP fusion protein, we further demonstrate that yhp23 colocalizes with ER within the nuclei of yeast, and that this colocalization is reversed by estradiol treatment. Finally, ectopic expression of human p23 in MCF-7 breast cancer cells increases transcriptional activation by endogenous ER. Together, these results strongly suggest that p23 plays an important role in ER signal transduction.</p>				
14. SUBJECT TERMS Breast Cancer				15. NUMBER OF PAGES 30
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

✓ Where copyrighted material is quoted, permission has been obtained to use such material.

✓ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

✓ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

✓ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

✓ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

✓ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
PI - Signature

9/17/99  
Date

Table of Contents:

Cover.....	page 1
Standard Form (SF) 298.....	page 2
Foreword.....	page 3
Table of Contents.....	page 4
Introduction.....	page 5
Body.....	page 6
Figure 1.....	page 12
Figure 2.....	page 13
Figure 3.....	page 14
Figure 4.....	page 15
Figure 5.....	page 16
Figure 6.....	page 17
Appendices	
Key Research Accomplishments.....	page 18
Reportable Outcomes.....	page 18

### Introduction

Estrogen hormone, which can act as both an initiator and progressor of cell transformation, is believed to play a central role in the development of breast cancer. The cellular effects of estrogen are mediated by estrogen receptor  $\alpha$  (ER $\alpha$ ), as well as the recently-discovered estrogen receptor  $\beta$  (ER $\beta$ ). Although ER is known to act as an estrogen-dependent transcription factor, much remains to be elucidated concerning its function. Through the isolation and characterization of protein factors which modulate ER activity, we expect to better understand the mechanisms by which estrogen hormone contributes breast cancer. To identify proteins that affect ER function, we have carried out a dosage suppression screen in yeast. In this manner, we have isolated the yeast homologue of p23 (yhp23) as a positive regulator of ER function. We are currently characterizing yhp23's role in ER signaling as it is reconstituted in yeast. The knowledge gained will then be used to study the role of human p23 in ER signaling in breast cancer.

## Body

The estrogen signal is mediated by the estrogen receptor (ER), a ligand-inducible transcription factor. In the absence of estradiol, ER is found predominantly in the nucleus(1,2), as part of a multiprotein complex consisting of a dimer of Hsp90(3), a p23 monomer(4), and one of several immunophilins, including Cyp-40(5) and FKBP52(6). It has been proposed that this Hsp90-based chaperone complex inactivates ER's transcriptional regulatory capabilities and maintains ER in a conformation competent for steroid binding(7). Upon binding estradiol, ER dissociates from this complex, dimerizes and recognizes specific DNA sequences(8), termed estrogen-response elements (EREs), within the promoters of estrogen-responsive genes. Once bound to an ERE, ER is believed to modulate transcription of the linked gene through direct or indirect interactions with general transcriptional factors(9,10).

To identify proteins that affect ER function, we carried out a dosage suppression screen in yeast, exploiting the ability of human ER to function within the yeast system. The mutant ER used in our dosage suppression screen contains a glycine to valine substitution at position 400 (G400V ER). This mutation is believed to alter the conformation of the ligand binding domain, resulting in decreased hormone binding by the receptor, with a corresponding reduction in G400V ER's ability to activate transcription in response to estradiol(11). This mutant was selected as the substrate for the screen because it affects an early step in the ER signaling pathway, namely steroid binding, and therefore has the potential to result in the isolation of factors important for either steroid binding or transcriptional activation.

### Yeast dosage suppression screen.

The relative activities of wt ER and G400V ER in yeast, over a range of hormone concentrations, is shown in Figure 1A. Compared to wt ER, G400V ER requires a 100-fold increase in 17- $\beta$ -estradiol concentration before receptor transcriptional activation is observed. At saturating ligand concentrations, however, G400V ER is able to reach the same maximal activity as wt ER, suggesting that once the block to steroid binding is overcome, the receptor is able to act as efficiently as wt ER in entering the functional interactions downstream of estradiol binding that are necessary for transcriptional activation.

The G400V ER phenotype is most apparent at a concentration of 1 nM 17- $\beta$ -estradiol, where wt ER shows maximal transcriptional response, but G400V ER displays only minimal transcriptional activity (Figure 1A). Exploiting this phenotypic difference, we carried out a dosage suppression screen to identify yeast proteins that, when overexpressed, would increase the transcriptional activity of G400V ER, thereby suppressing the mutant phenotype. The yeast strain containing G400V ER and an estrogen-responsive  $\beta$ -galactosidase reporter gene was transformed with a high-copy yeast genomic library and assayed for G400V ER transcriptional activity on X-gal indicator plates containing 1 nM 17- $\beta$ -estradiol. Under these conditions, yeast colonies expressing the wt ER are blue, while the G400V ER-expressing yeast appear white (Figure 1B). Blue colonies were considered to be potential suppressor candidates.

The strongest suppressor, designated 4.3, was found to increase G400V ER transcriptional activity 10-fold, bringing G400V ER transcriptional activation to one third the wt ER level at 1 nM 17- $\beta$ -estradiol (Figure 1B and C). The suppressing fragment was found to be an 8,147 base pair genomic fragment of chromosome XI(12), containing

multiple open reading frames (ORFs). Deletional analysis revealed ORF YKL 117w to be the suppressing gene (Figure 1D).

A search of the Swissprot database revealed YKL 117w to be the yeast homologue of the human p23 protein (yhp23)(13), a component of the Hsp90-based molecular chaperone complex. Although p23's specific function is not known, *in vitro* studies suggest that it is crucial to the stability of the aporeceptor complex of unliganded steroid receptors. Removal of p23 greatly reduces the formation of stable aporeceptor complexes of glucocorticoid(14,15,17) and progesterone receptors(13,19) (GR and PR). In addition, *in vitro* studies have suggested that p23 possesses abilities typical of molecular chaperones, as it is capable of interacting with denatured  $\beta$ -galactosidase, suppressing its aggregation, and maintaining it in an intermediate, folding-competent conformation(20). The relative importance of these two aspects of p23 function in steroid receptor signaling has not been determined.

#### Characterization of yhp23's role in ER signaling.

Having identified yhp23 as the suppressing ORF, we cloned the YKL 117w gene, with an amino-terminal hemagglutinin (HA) epitope tag (HA-yhp23), into a yeast expression vector containing a constitutively active glycerol-phosphate dehydrogenase (GPD) promoter. We then established yeast strains that overexpresses HA-yhp23 in the presence of G400V ER or wt ER, along with a reporter plasmid containing the  $\beta$ -galactosidase gene under control of an ERE. As seen in Figure 2A, overexpression of HA-yhp23 increases G400V ER transcriptional activity by 10-fold. Western blots, probed with antibodies specific for ER and HA, demonstrate that the levels of G400V ER are unchanged (Figure 2B). Further comparison of G400V ER activity in the presence and absence of yhp23 overexpression, over a range of hormone concentrations, reveals that yhp23's importance to G400VER signaling decreases at high estradiol concentrations (Figure 2C).

Wt ER activity was affected in a similar manner as G400V ER, albeit less dramatically (Figure 2D). At 0.1 nM 17- $\beta$ -estradiol, wt ER activity is increased by approximately 70% in the presence of overexpressed yhp23, with no increase observed at the higher concentrations of 1 nM and 10 nM 17- $\beta$ -estradiol. In contrast to G400V ER, however, an increase in wt ER activity was observed at .01 nM 17- $\beta$ -estradiol. To more closely examine the effect of yhp23 on wt ER activity at this low hormone concentration, we compared wt ER ligand-independent activity to wt ER activity at .01 nM 17- $\beta$ -estradiol. As seen in Figure 2E, overexpression of yhp23 increases wt ER ligand-independent activity by approximately two-fold, and ligand-dependent activation by three-fold in the presence of .01 nM 17- $\beta$ -estradiol. These results suggest that increased levels of yhp23 can facilitate wt ER ligand-independent activity and potentiate ER signaling at low levels of hormone.

Importantly, yhp23 does not appear to have any effect upon the activity of the ER AF-1 domain. As shown in Figure 2F, yhp23 overexpression does not affect the constitutive, AF-1 dependent, transcriptional activation by the amino-terminal 115 residues of ER fused to a Lex DNA binding domain. This finding, taken together with the observed hormone concentration-dependent effect of yhp23 overexpression (Figure 2C and 2D), suggests that yhp23 affects the ER signal transduction pathway at the step of ligand binding.

Yhp23 overexpression increases ligand binding by both G400V ER and wt ER.

Estradiol binding by G400V ER and wt ER in the presence and absence of yhp23 overexpression was measured *in vivo*. The yeast strains were incubated for one hour in media containing [<sup>3</sup>H]-17- $\beta$ -estradiol, washed three times to remove unbound steroid, and the amount of estradiol bound to G400V ER and wt ER was measured by quantifying [<sup>3</sup>H]-17- $\beta$ -estradiol content by liquid scintillation counting.  $\beta$ -galactosidase assays were carried out in parallel on the same cells to correlate effects of ligand binding to transcriptional activation.

As seen in Figure 3A, ligand binding by G400V ER, at a concentration of 1 nM [<sup>3</sup>H]-17- $\beta$ -estradiol, was increased by approximately five-fold in the presence of overexpressed yhp23. This increase in ligand binding was found to correlate with a seven-fold increase in G400V ER transcriptional activity (Figure 3B). Immunoblot analysis showed that the levels of G400V ER were unchanged by yhp23 overexpression (data not shown).

As seen in Figure 3C, yhp23 overexpression increased wt ER ligand binding, at a concentration of 0.1 nM [<sup>3</sup>H]-17- $\beta$ -estradiol, by approximately 50%.  $\beta$ -galactosidase assay of these cells demonstrated a corresponding 70% increase in transcriptional activity (Figure 3D). Again, immunoblot analysis showed no difference in the level of ER expression exhibited by the two strains (data not shown). These results indicate that yhp23 overexpression increases ER transcriptional activity by increasing the total number of ligand-bound receptors.

The magnitude of yhp23's effect on wt ER signaling is a function of wt ER and estradiol concentrations.

Having demonstrated that overexpression of yhp23 increases wt ER transcriptional activity, we next asked if a decrease in yhp23 concentration would reduce wt ER activity. To this end, we compared wt ER transcriptional activity in the yhp23 knockout strain (KO) to that in the parental strain (PA)(21), as well as the parental strain overexpressing HA-yhp23 (PA+HA-yhp23 strain). In this way, we were able to assay wt ER function in 1) the absence of yhp23 (KO), 2) the presence of endogenous levels of yhp23 (PA), and 3) the presence of both endogenous yhp23 and overexpressed HA-yhp23 (PA+HA-yhp23) (Figure 4B). A wt ER expression vector and an ERE- $\beta$ -galactosidase reporter plasmid were introduced into these three yeast strains and wt ER transcriptional activity was assayed at 0.1 nM 17- $\beta$ -estradiol. The activity of wt ER within the three different strains at this hormone concentration is shown in Figure 4A. In the absence of yhp23 (KO), wt ER signaling still occurs, demonstrating that wt ER is capable of functioning in a yhp23-independent manner. Increasing levels of yhp23, however, results in increased activity of ER, with the PA+HA-yhp23 strain displaying ER activity 2.7-fold higher relative to the KO strain. This increase in wt ER activity is not a function of increased receptor levels, since wt ER levels were unchanged in the absence or presence of yhp23 (data not shown). Thus, wt ER transcriptional activity increases in direct proportion to the concentration of yhp23.

We next asked if the effect of yhp23 upon ER signaling is also a function of wt ER concentration. This was accomplished by repeating the above experiment in media containing only raffinose as a carbon source, resulting in low levels of wt ER expression. As seen in Figure 4C, a similar pattern of yhp23-dependent ER activation was observed when ER is expressed at low concentrations (Figure 4C). However, the magnitude of the effect of yhp23 on wt ER transcriptional activation is greater under these conditions, as the



PA+HA-yhp23 strain exhibits ER activity five-fold higher than the KO strain (Figure 4D). Thus, the magnitude of yhp23's effect on wt ER transcriptional activity is greater at low, rather than high, wt ER concentrations.

The idea that the importance of yhp23 to wt ER function correlates inversely to hormone concentration (Figure 2C and D) was further confirmed when the activity of wt ER within the KO and PA+HA-yhp23 strains was assayed at both 0.1 nM and 1 nM 17- $\beta$ -estradiol, under conditions of low wt ER expression. As seen in Figure 4E, the five-fold induction of wt ER transcriptional activity observed within the PA+HA-yhp23 strain at 0.1 nM 17- $\beta$ -estradiol decreases to only a two-fold induction at the higher concentration of 1 nM 17- $\beta$ -estradiol. When activities are compared at yet higher hormone concentrations, no difference in activity is observed between the KO and PA+HA-yhp23 strains at 10 nM 17- $\beta$ -estradiol (data not shown). Thus, the effect of yhp23 overexpression on wt ER transcriptional activation is inversely proportional to hormone concentration.

Interestingly, wt ER ligand-independent activity also increases with yhp23 overexpression (Figure 4F). This effect on transcription is not observed in the absence of wt ER expression, suggesting that yhp23 is operating via wt ER to induce estradiol-independent transcriptional activation.

Thus, the relationship of yhp23 to wt ER signal transduction is dependent not only on concentrations of yhp23, but upon the level of wt ER and estradiol as well. Our data demonstrate that the effect of yhp23 upon wt ER function is most pronounced when wt ER activity is examined at low estradiol and wt ER concentrations.

ER and yhp23 colocalize within the nucleus of yeast.

Prior genetic and biochemical studies have demonstrated that aporeceptor complex formation is conserved in yeast(22). Hsp82, the yeast homologue of Hsp90, has been shown to associate with hormone-free ER and GR in yeast. In addition, genetic studies indicate that ER and GR signaling is reduced in yeast strains expressing only 5% of the wt level of Hsp82(23). Compelling genetic evidence also exists for the role of the yeast Hsp70(24), p60(25), Hsp40(24), and immunophilin(26) homologues in steroid signaling in yeast, with the majority of these proteins having been shown to associate with GR in the absence of hormone(21,27).

Given human p23's presence in the aporeceptor complexes of PR(13) and GR(15), and having shown that yhp23 affects ER function, we proceeded to determine if yhp23 and ER colocalize *in vivo*. To determine the cellular distribution of yhp23 in yeast, we created a yhp23-green fluorescent protein (GFP) fusion protein by subcloning GFP at the carboxy-terminus of the yhp23 protein. Expression of the fusion protein was confirmed by Western blot. Importantly, the yhp23-GFP fusion protein is also able to suppress the G400V ER phenotype (not shown), proving that addition of the GFP moiety does not eliminate yhp23's ability to functionally interact with G400V ER.

We constructed several yeast strains that express yhp23-GFP either alone, or in combination with G400V ER, wt ER, or wt GR. Figure 5A demonstrates that the distribution of yhp23-GFP in the absence of steroid receptor expression is largely cytoplasmic, though a small proportion of signal corresponding to the nucleus is also evident. Strikingly, upon coexpression of G400V ER or wt ER, yhp23-GFP becomes predominantly limited to the nucleus, thereby colocalizing with the receptor (Figure 5B and D). Importantly, this pattern of nuclear localization was not seen when G400V ER was coexpressed with just the GFP protein, indicating that yhp23 is responsible for the localization of the fusion protein to the nucleus (Figure 5C). Additionally, when cells

coexpressing wt ER and yhp23-GFP were incubated in 17- $\beta$ -estradiol, yhp23-GFP redistributed to the cytoplasm (Figure 5E), reestablishing the pattern seen in yeast lacking ER expression (Figure 5A). As a final control, yhp23-GFP coexpressed with GR, a steroid receptor that exists outside the nucleus in the steroid-free state, did not localize to the nucleus (Figure 5F), but instead showed a cytoplasmic distribution similar to GR. Thus the colocalization of yhp23 and ER is consistent with the proposed role of yhp23 as a member of ER aporeceptor complex.

Increased ER transcriptional activation by human p23 overexpression in MCF-7 cells.

To establish whether p23 affects ER signal transduction in mammalian cells, we examined the ability of human p23 to increase ER-mediated transcriptional enhancement when overexpressed in cultured mammalian cells. ER-containing MCF-7 cells were transfected with the reporter plasmid ERE-thymidine kinase-Luciferase and a plasmid encoding human p23. Transfected cells were treated with 0.1 nM 17- $\beta$ -estradiol or ethanol vehicle for 24 hours, and transcriptional activity was quantified by luciferase activity. As shown in Figure 6, both hormone-dependent and hormone-independent ER transcriptional activity are increased roughly two-fold when p23 is overexpressed. This likely represents an underestimate of p23's importance to ER function, as these results are obtained in a cell line that contains endogenous p23 (not shown). These findings suggest that p23 is a limiting factor for ER signal transduction and therefore, subsequent ER-mediated transcriptional enhancement.

## Bibliography:

1. Welshons, W. V., Lieberman, M. E., and Gorski, J. (1984) *Nature* **307**(5953), 747-749
2. King, W. J., and Greene, G. L. (1984) *Nature* **307**(5953), 745-747
3. Catelli, M. G., Binart, N., Jung-Testas, I., Renoir, J. M., Baulieu, E. E., Feramisco, J. R., and Welch, W. J. (1985) *EMBO J.* **4**(12), 3131-3135
4. Nair, S. C., Toran, E. J., Rimerman, R. A., Hjermstad, S., Smithgall, T. E., and Smith, D. F. (1996) *Cell Stress Chaperones* **1**(4), 237-250
5. Ratajczak, T., Carrello, A., Mark, P. J., Warner, B. J., Simpson, R. J., Moritz, R. L., and House, A. K. (1993) *J. Biol. Chem.* **268**(18), 13187-13192
6. Ratajczak, T., and Carrello, A. (1996) *J. Biol. Chem.* **271**(6), 2961-2965
7. Pratt, W. B., and Toft, D. O. (1997) *Endocr Rev* **18**(3), 306-360
8. Kumar, V., and Chambon, P. (1988) *Cell* **55**(1), 145-156
9. Ing, N. H., Beekman, J. M., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. (1992) *J. Biol. Chem.* **267**(25), 17617-17623
10. Elliston, J. F., Fawell, S. E., Klein-Hitpass, L., Tsai, S. Y., Tsai, M. J., Parker, M. G., and O'Malley, B. W. (1990) *Mol. Cell. Biol.* **10**(12), 6607-6612
11. Tora, L., Mullick, A., Metzger, D., Ponglikitmongkol, M., Park, I., and Chambon, P. (1989) *EMBO J.* **8**(7), 1981-1986
12. Jacquier, A., Legrain, P., and Dujon, B. (1992) *Yeast* **8**(2), 121-132
13. Johnson, J. L., Beito, T. G., Krco, C. J., and Toft, D. O. (1994) *Mol. Cell. Biol.* **14**(3), 1956-1963
14. Dittmar, K. D., Hutchison, K. A., Owens-Grillo, J. K., and Pratt, W. B. (1996) *J. Biol. Chem.* **271**(22), 12833-12839
15. Dittmar, K. D., Demady, D. R., Stancato, L. F., Krishna, P., and Pratt, W. B. (1997) *J. Biol. Chem.* **272**(34), 21213-21220
16. Hutchison, K. A., Stancato, L. F., Owens-Grillo, J. K., Johnson, J. L., Krishna, P., Toft, D. O., and Pratt, W. B. (1995) *J. Biol. Chem.* **270**(32), 18841-18847
17. Hutchison, K. A., Dittmar, K. D., and Pratt, W. B. (1994) *J. Biol. Chem.* **269**(45), 27894-27899
18. Johnson, J. L., and Toft, D. O. (1994) *J. Biol. Chem.* **269**(40), 24989-24993
19. Johnson, J. L., and Toft, D. O. (1995) *Mol. Endocrinol.* **9**(6), 670-678
20. Freeman, B. C., Toft, D. O., and Morimoto, R. I. (1996) *Science* **274**(5293), 1718-1720
21. Bohen, S. P. (1998) *Mol. Cell. Biol.* **18**(6), 3330-3339
22. Caplan, A. J. (1997) *Trends Endocrine Metab.* **8**, 271-276
23. Picard, D., Khursheed, B., Garabedian, M. J., Fortin, M. G., Lindquist, S., and Yamamoto, K. R. (1990) *Nature* **348**(6297), 166-168
24. Kimura, Y., Yahara, I., and Lindquist, S. (1995) *Science* **268**(5215), 1362-1365
25. Chang, H. C., Nathan, D. F., and Lindquist, S. (1997) *Mol. Cell. Biol.* **17**(1), 318-325
26. Duina, A. A., Chang, H. C., Marsh, J. A., Lindquist, S., and Gaber, R. F. (1996) *Science* **274**(5293), 1713-1715
27. Chang, H. C., and Lindquist, S. (1994) *J. Biol. Chem.* **269**(40), 24983-24988




Figure 1: Isolation of a yeast genomic fragment that suppresses the G400V ER phenotype.

A) Transcriptional activity of wt ER and G400V ER as a function of 17- $\beta$ -estradiol concentration. The W303a yeast strain was transformed with a galactose-inducible expression vector containing either wt or G400V ER, along with an ERE-containing  $\beta$ -galactosidase reporter plasmid. Transcriptional activation by wt ER (filled circles) and G400V ER (open circles) in response to increasing 17- $\beta$ -estradiol concentration was determined by liquid  $\beta$ -galactosidase assay as described in Materials and Methods. Note that G400V ER requires a hundred-fold higher estradiol concentration to induce transcriptional activation compared to wt ER. The dosage suppression screen was carried out in the presence of 1 nM 17- $\beta$ -estradiol, the conditions under which the G400V ER phenotype is most pronounced. B) The relative activity of wt ER, G400V ER, and G400V ER + suppressor 4.3. Four independent colonies on X-Gal indicator plates containing 1 nM 17- $\beta$ -estradiol are shown and represent wt ER + empty library plasmid (wt ER); G400V ER + empty library plasmid (G400V ER); and G400V ER + suppressor plasmid 4.3 (G400V ER + 4.3). C) Transcriptional activity of wt ER, G400V ER, and G400V ER in presence of suppressor 4.3. Liquid  $\beta$ -galactosidase assays were performed on yeast strains containing wt ER + empty library plasmid, G400V ER + empty library plasmid, and G400V ER + 4.3, at 1 nM 17- $\beta$ -estradiol. Suppressor 4.3 increases G400V ER activity ten-fold, bringing its activity to nearly one third that of wt ER. D) Identification of YKL 117w as the G400V ER suppressor. The sequence of the yeast genomic fragment contained within the suppressor 4.3 was determined by aligning the 5' and 3' ends of the insert to the yeast genomic sequence database. Suppressor 4.3 contains an 8,147 bp fragment comprising 4 complete open reading frames (YKL 121w, PMT1, VPH2, and YKL 117w), a partial open reading frame (YKL 116w), and a tRNA-Ala gene (shaded box). The relative positions and orientation of the genes within the 4.3 fragment are shown schematically (fragment 1). Identification of the gene responsible for suppressing the G400V ER phenotype was accomplished by constructing 5' and 3' deletion derivatives of the 4.3 suppressor (fragments 2-5) and assaying their ability to increase G400V ER transcriptional activity at 1 nM 17  $\beta$ -estradiol. "Yes" indicates the fragment is capable of suppressing the G400V ER phenotype, while "No" represents fragments that fail to increase G400V ER transcriptional activity. YKL 117w was present within the suppressing fragments (1-4), but absent within the fragment that did not suppress (5), suggesting that its gene product is responsible for increasing G400V ER transcriptional activation. YKL 117w encodes the yeast homologue of the human p23 protein (yhp23/SBA1).




Figure 2: Effect of yhp23 overexpression on G400V ER and wt ER transcriptional activity.

An HA-tagged yhp23 gene was cloned into the yeast expression vector pRS314 downstream of the GPD promoter. Yeast strains were then constructed which coexpress G400V ER or wt ER with the HA-tagged yhp23, in the presence of a  $\beta$ -galactosidase reporter gene under the control of the appropriate hormone response element (ERE or GRE). A) Overexpression of HA-yhp23 increases G400V ER transcriptional activation. The activity of G400V ER in the presence and absence of overexpressed yhp23 was determined by liquid  $\beta$ -galactosidase assay at a concentration of 1 nM 17- $\beta$ -estradiol. Overexpression of yhp23 increased G400V ER activity approximately ten-fold. B) Increased transcriptional activation of G400V ER by yhp23 is not a function of increased ER levels. Whole cell lysates were prepared from the yeast strains described in (A). Equal amounts of proteins were separated on SDS/4-20% gradient polyacrylamide gel, transferred to Immobilon paper, and probed with an ER-specific rabbit polyclonal antiserum (top panel) or a monoclonal antibody directed against the HA-epitope on yhp23 (bottom panel) and visualized by enhanced chemiluminescence. C) Dose response curves for G400V ER. The activity of G400V ER in the absence (open circles) and presence (closed circles) of overexpressed yhp23, at the indicated 17- $\beta$ -estradiol concentrations is shown. The increased transcriptional activity displayed by G400V ER in the presence of HA-yhp23 overexpression is seen to be greatest at low hormone concentrations, and is lost completely at the highest hormone concentrations assayed. D) Dose response curves for wt ER. The activity of wt ER in the absence (open squares) and presence (closed squares) of overexpressed HA-yhp23, at the indicated 17- $\beta$ -estradiol concentrations is shown. The effect of HA-yhp23 overexpression is seen to be greatest at low hormone concentrations, and is lost completely at the highest hormone concentrations assayed. E) Overexpression of HA-yhp23 increases ligand-independent activity of ER. The activity of ER in the absence and presence of .01 nM 17- $\beta$ -estradiol is shown. Ligand-independent transcriptional activity by ER is approximately three-fold higher in the presence of HA-yhp23 overexpression. Addition of .01 nM 17- $\beta$ -estradiol resulted in a greater level of ER ligand-dependent activity in the HA-yhp23 overexpressing strain, suggesting that yhp23 overexpression increases the sensitivity of ER to low concentrations of 17- $\beta$ -estradiol. F) HA-yhp23 overexpression does not affect the AF-1 activity of ER. The amino terminal 115 residues of ER, containing the AF-1 activity of ER in yeast, were fused to a Lex DNA Binding Domain (see Material and Methods). Constitutive AF-1 activity resulted in transcription of a reporter  $\beta$ -galactosidase gene downstream of a Lex A binding site, which was unaffected by overexpression of HA-yhp23.




Figure 3: Overexpression of yhp23 increases estradiol binding by G400V ER and wt ER *in vivo*.

The total amount of estradiol bound by G400V ER and wt ER in the presence and absence of yhp23 overexpression was determined by *in vivo* ligand binding assay, using the same yeast strains described in Figure 2. After a one hour incubation in the presence of [ $^3$ H]-17- $\beta$ -estradiol, cells were washed to remove unbound ligand, and amount of bound estradiol was determined by liquid scintillation counting. Liquid  $\beta$ -galactosidase assays were carried out, in parallel, on an aliquot of the same [ $^3$ H]-17- $\beta$ -estradiol incubated cells in order to correlate levels of ligand binding to resulting levels of transcriptional activation. A) HA-yhp23 overexpression increases ligand binding by G400V ER. Cells expressing G400V ER in the presence and absence of HA-yhp23 overexpression were assayed for ligand binding in the presence of 1 nM [ $^3$ H]-17- $\beta$ -estradiol. Ligand binding by G400V ER is seen to increase approximately five-fold in the presence of overexpressed HA-yhp23. B) Increased ligand binding by G400V ER in the presence of HA-yhp23 overexpression correlates with an increase in transcriptional activation by the receptor. Liquid  $\beta$ -galactosidase assays, carried out on an aliquot of cells described in (A), demonstrate a corresponding seven-fold increase in transcriptional activity by G400V ER. C) HA-yhp23 overexpression increases ligand binding by wt ER. Cells expressing wt ER in the presence and absence of HA-yhp23 overexpression were assayed for ligand binding in the presence of 0.1 nM [ $^3$ H]-labeled 17- $\beta$ -estradiol. Ligand binding by wt ER is seen to increase by approximately 50% in the presence of overexpressed HA-yhp23. D) Increased ligand binding by wt ER in the presence of HA-yhp23 overexpression correlates with an increase in transcriptional activation by the receptor. Liquid  $\beta$ -galactosidase assays, carried out on an aliquot of cells described in (C), demonstrate a corresponding 70% increase in transcriptional activity by wt ER.




Figure 4: Yhp23's effect on wt ER activity is a function of yhp23, ER, and estradiol concentrations.

A) The effect of yhp23 on wt ER transcriptional activation at high ER concentrations. ER transcriptional activity as a function of yhp23 concentration was determined by liquid  $\beta$ -galactosidase assay in cells incubated in galactose/raffinose-supplemented media containing 0.1 nM 17- $\beta$ -estradiol. B) KO, PA and PA+HA-yhp23 strains express different levels of yhp23. Equal amounts of whole cell lysates from the KO, PA, and PA+HA-yhp23 strains were analyzed by immunoblotting using anti-yhp23 polyclonal antibody as described in Materials and Methods. The upper band seen in the PA+HA-yhp23 lane corresponds to the HA-tagged yhp23. C) The effect of yhp23 on wt ER transcriptional activity at low wt ER concentration. ER transcriptional activity as a function of yhp23 concentration was determined by liquid  $\beta$ -galactosidase assay in cells incubated in raffinose-supplemented media containing 0.1 nM 17- $\beta$ -estradiol. Under these conditions ER expression is 10-fold lower as compared to cells grown in the presence of galactose (not shown). D) Yhp23 induction of wt ER transcriptional activity is inversely proportional to wt ER concentration. The fold induction of yhp23 on ER transcriptional activity at 0.1 nM 17- $\beta$ -estradiol under conditions of high ER expression (galactose, gray bars) or low ER expression (raffinose, black bars) is standardized to the ER activity in the KO strain. E) The effect of yhp23 on wt ER function is inversely proportional to ligand concentration. The fold induction of ER transcriptional activation in the PA+HA-yhp23 vs KO strains at 0.1 nM and 1 nM 17- $\beta$ -estradiol was determined under conditions of low ER expression (raffinose media). Results indicate that the fold-induction of ER transcriptional activation in the presence of yhp23 overexpression is significantly greater at 0.1 nM 17- $\beta$ -estradiol than 1 nM 17- $\beta$ -estradiol. F) Yhp23 overexpression increases estradiol-independent wt ER transcriptional activation. The effect of yhp23 overexpression on ERE-dependent transcriptional activation in the presence and absence of ER is shown. KO and PA+HA-yhp23 strains containing the ERE-reporter construct, were transformed with either the empty expression vector or with the ER-containing expression vector and assayed for  $\beta$ -galactosidase activity in galactose/raffinose media without estradiol.




Figure 5: ER and yhp23-GFP colocalize within the nucleus of yeast.

To examine yhp23 subcellular localization in yeast, a yhp23-GFP fusion protein was constructed. Yeast strains were created that express yhp23-GFP (A) or GFP (C) either alone, or in combination with G400V ER (B-C), wt ER (D-E), or GR (F). Cells were grown in galactose/raffinose-containing media, in the absence or presence of 17- $\beta$ -estradiol. Cells were fixed, permeabilized, and incubated with the appropriate receptor primary antibody, a corresponding Texas-red-conjugated secondary antibody and the DNA in the nucleus was stained with Hoechst dye H334211. The GFP, Texas-red and Hoechst fluorescent signals were visualized using a Zeiss Axioplan 2 Fluorescent microscope. Note that yhp23-GFP is expressed throughout the cytoplasm in the absence of ER expression. In the presence of coexpressed G400V ER as well as wt ER, yhp23-GFP becomes localized to the nucleus. Incubation of the wt ER strain in 1  $\mu$ M 17- $\beta$ -estradiol results in the redistribution of yhp23-GFP from the nucleus to the cytoplasm, thereby reversing the ER-yhp23-GFP colocalization observed in the absence of estradiol.






Figure 6: Activation of ER transcriptional enhancement by ectopic p23 expression.

ER-containing MCF-7 cells ( $2.5 \times 10^5$  cells/6 cm dish) were transiently transfected using the lipid Trans-IT 100 with 5  $\mu$ g of the ERE-containing luciferase reporter plasmid and 2  $\mu$ g of a pCMV expression vector (white) or pCMV-HA-p23 expression vector (grey). Cells were incubated for 24 hours in the presence of 0.01 nM 17- $\beta$ -estradiol or ethanol vehicle and harvested. ER transcriptional activation was measured by luciferase assay, normalized to total protein concentration in each sample and expressed as relative luminescence units (RLU). Data represents the mean of an experiment done in triplicate, which was repeated four times.

## 7) Appendices

### Key research accomplishments:

- Isolation of yhp23, the yeast homologue of human p23, as a protein whose overexpression can greatly enhance the activity of G400V ER, by increasing the number of activated receptors.
- Demonstration that yhp23 can similarly affect wt ER, especially under conditions of low ER expression, and low estradiol concentrations.
- Using a yhp23-GFP fusion protein, we were able to show that yhp23 and ER colocalize in the nuclei of yeast in a manner consistent with yhp23 being a member of the aporeceptor complex in yeast.
- Demonstration that human p23 overexpression in MCF-7 cells can increase the activity, both ligand-dependent and independent, of endogenous ER.

### Reportable outcomes:

Knoblauch, R. and Garabedian, M.J. 1999. A Role for the Hsp90-Associated Co-chaperone p23 in Estrogen Receptor Signal Transduction. *Mol. Cell. Biol.* 19:3748-3759.

Knoblauch, R. and Garabedian, M.J. Chaperoning the Estrogen Receptor into Action. Nuclear Receptor Gene Family Keystone Symposia. March 28 - April 3, 1998

## Role for Hsp90-Associated Cochaperone p23 in Estrogen Receptor Signal Transduction

ROLAND KNOBLAUCH AND MICHAEL J. GARABEDIAN\*

*Department of Microbiology and Kaplan Comprehensive Cancer Center, New York University  
School of Medicine, New York, New York 10016*

Received 31 July 1998/Returned for modification 6 October 1998/Accepted 12 January 1999

The mechanism of signal transduction by the estrogen receptor (ER) is complex and not fully understood. In addition to the ER, a number of accessory proteins are apparently required to efficiently transduce the steroid hormone signal. In the absence of estradiol, the ER, like other steroid receptors, is complexed with Hsp90 and other molecular chaperone components, including an immunophilin, and p23. This Hsp90-based chaperone complex is thought to repress the ER's transcriptional regulatory activities while maintaining the receptor in a conformation that is competent for high-affinity steroid binding. However, a role for p23 in ER signal transduction has not been demonstrated. Using a mutant ER (G400V) with decreased hormone binding capacity as a substrate in a dosage suppression screen in yeast cells (*Saccharomyces cerevisiae*), we identified the yeast homologue of the human p23 protein (yhp23) as a positive regulator of ER function. Overexpression of yhp23 in yeast cells increases ER transcriptional activation by increasing estradiol binding *in vivo*. Importantly, the magnitude of the effect of yhp23 on ER transcriptional activation is inversely proportional to the concentration of both ER and estradiol in the cell. Under conditions of high ER expression, ER transcriptional activity is largely independent of yhp23, whereas at low levels of ER expression, ER transcriptional activation is primarily dependent on yhp23. The same relationship holds for estradiol levels. We further demonstrate that yhp23 colocalizes with the ER *in vivo*. Using a yhp23-green fluorescent protein fusion protein, we observed a redistribution of yhp23 from the cytoplasm to the nucleus upon coexpression with ER. This nuclear localization of yhp23 was reversed by the addition of estradiol, a finding consistent with yhp23's proposed role as part of the aporeceptor complex. Expression of human p23 in yeast partially complements the loss of yhp23 function with respect to ER signaling. Finally, ectopic expression of human p23 in MCF-7 breast cancer cells increases both hormone-dependent and hormone-independent transcriptional activation by the ER. Together, these results strongly suggest that p23 plays an important role in ER signal transduction.

Estrogen is a steroid hormone responsible for the proper function of a variety of mammalian physiological processes. In addition to its central role in reproduction (6, 33), estrogen also affects the cardiovascular (19), skeletal (47), immune (9), and nervous (57) systems and plays a role in the initiation and progression of breast cancer (58).

The estrogen signal is mediated by the estrogen receptor (ER), a ligand-inducible transcription factor. In the absence of estradiol, the ER is found predominantly in the nucleus (32, 56), as part of a multiprotein complex consisting of a dimer of Hsp90 (6), a p23 monomer (42), and one of several immunophilins, including Cyp-40 (49) and FKBP52 (48). It has been proposed that this Hsp90-based chaperone complex inactivates the ER's transcriptional regulatory capabilities and maintains the ER in a conformation competent for steroid binding (46). Upon binding estradiol, ER dissociates from this complex, dimerizes, and recognizes specific DNA sequences (35), termed estrogen-response elements (EREs), within the promoters of estrogen-responsive genes. Once bound to an ERE, ER is believed to modulate transcription of the linked gene through direct or indirect interactions with general transcriptional factors (15, 25).

Although many aspects of ER signaling are not yet understood, it appears that the proteins essential to ER function are conserved among eukaryotes to such an extent that introduc-

tion of ER into *Saccharomyces cerevisiae*, which lacks endogenous ER, is sufficient for the faithful reconstitution of estrogen signaling within these cells (18, 41). When expressed in yeast cells, the human ER will activate transcription from EREs located in reporter gene promoters in response to estradiol. This ability of ER to function within yeast cells allows a wide variety of genetic approaches to be taken toward defining the mechanisms of signal transduction and transcriptional regulation by the receptor.

To identify proteins that affect ER function, we have carried out a dosage suppression screen in yeast cells. In this technique, a mutant ER protein, with a reduced ability to activate transcription, is used as a substrate to isolate a yeast gene product(s) that is capable of overcoming this mutant phenotype by favoring the interaction between ER and these factors, thus reconstituting receptor transcriptional activity. The mutant ER used in our dosage suppression screen contains a glycine-to-valine substitution at position 400 (G400V ER). This mutation is believed to alter the conformation of the ligand-binding domain, resulting in decreased hormone binding by the receptor, with a corresponding reduction in G400V ER's ability to activate transcription in response to estradiol (54). This mutant was selected as the substrate for the screen because it affects an early step in the ER signaling pathway, namely steroid binding, and therefore has the potential to result in the isolation of factors important for either steroid binding or transcriptional activation. We anticipate that characterization of these proteins will ultimately lead to a more complete understanding of the ER signal transduction pathway.

\* Corresponding author. Mailing address: Department of Microbiology and Kaplan Comprehensive Cancer Center, NYU School of Medicine, 550 First Ave., New York, NY 10016. Phone: (212) 263-7662. Fax: (212) 263-8276. E-mail: garabm01@mcrcr.med.nyu.edu.

Using G400V ER as our dosage suppression screen substrate, we have isolated a yeast gene that, when overexpressed, is capable of increasing both G400V and wild-type (wt) ER's ability to activate transcription in response to estradiol. This gene product is the yeast homologue of the vertebrate p23 protein (yhp23) (28), a component of the Hsp90-based molecular chaperone complex associated with unliganded steroid receptors as part of the aporeceptor complex. We have examined the functional relationship between p23 and ER *in vivo* under a range of receptor, estradiol, and p23 concentrations. Our findings suggest that p23 plays a role in ER signal transduction.

## MATERIALS AND METHODS

**Yeast strains and growth conditions.** The W303a (a *ade2 leu2 his3 trp1 ura3*) yeast strain was used in experiments where indicated. The yhp23/SBA1 knockout (KO) and parental (PA) strains are described elsewhere (2). Standard genetic methods were used for growth and manipulation. Cultures were propagated at 30°C in rich medium (yeast extract-peptone-dextrose) or selective minimal medium with 2% glucose (or raffinose or galactose) supplemented with amino acids. To induce gene expression from vectors containing the Gal1-10 inducible promoter, yeast cells were grown in selective medium containing either 2% galactose–1% raffinose or 2% raffinose.

**Plasmid constructs.** The YKL117w gene was cloned from the 4.3 library plasmid by PCR with the following primers: 5'-GAAGATCTCCACCATGTAC CCATACGATGTTCTGACTATGCGTCCGATAAAGTTATTAAACCCTC AAGTTGC-3' (encoding a hemagglutinin [HA] epitope and containing a *Bgl*II site) and 5'-CCCCATGGTTACTCATTCTAGCACTCCAGGTTGATTT-3'. The PCR product was gel purified and subcloned into the pGEM-T Easy vector (Promega). The entire fragment was sequenced to ensure the fidelity of the PCR product. HA-yhp23 was released from this vector by digesting it with *Bgl*II (within primer) and *Pst*I (within the polylinker of pGEM-T Easy) and then subcloned into *Bgl*II/*Pst*I-digested pCMV5. HA-yhp23 was released from pCMV5 by the *Bgl*II/*Bam*HI digest and subcloned into the *Bam*HI site of the yeast expression vectors containing the glycerol-phosphate dehydrogenase promoter (GPD) pRS314<sub>GPD</sub>(Trp1) and pRS315<sub>GPD</sub>(Leu2). The yhp23-green fluorescent protein (GFP) fusion protein was created by subcloning the *Hind*III/*Xba*I fragment of GFP from pEGFP-N3 (Clontech) into a *Bgl*II/*Hind*III fragment of HA-yhp23 in the pGEM-T Easy vector and placing the HA-yhp23-GFP fusion protein into pCMV5 at the *Bgl*II/*Xba*I sites. The HA-yhp23-GFP fusion protein was excised from pCMV5 by using *Bgl*II/*Bam*HI and then subcloned into the *Bam*HI site of the yeast expression vector pRS314<sub>GPD</sub>. The ER<sub>1-115</sub>-Lex DNA binding domain fusion protein was constructed by excising the *Eco*RI/*Pvu*II fragment of pGEX-ER<sub>1-185</sub> (a kind gift from P. Kushner) and inserting it into the *Eco*RI- and *Xho*I-digested pEG 202 two-hybrid vector (20). The *Xho*I sticky end was first blunted to make ligation with the *Pvu*II blunt end possible.

An HA epitope was also placed at the amino terminus of the human p23 cDNA by PCR by using the following primers: 5'-GCCGATCCACCATGTAC CCATACGATGTTCTGACTATGCGCAGCCTGCTTCTGCAAAGTGGTAC GATCG-3' (containing a *Bgl*II site and encoding an HA epitope) and 5'-CACCA CCCATGTTGTTTCATCTCAGAG-3'. The same PCR and cloning strategy was used to create the HA-p23 yeast and mammalian expression vectors.

wt ER, G400V ER, and wt glucocorticoid receptor (GR) were expressed from vectors containing the Gal1-10 promoter, the 2 $\mu$ m plasmid replication origin from yeast cells, and either the *TRP1* (p2T-GAL) or *HIS3* (p2H-GAL) gene. Reporter plasmids ERE-CYC1-LacZ or GRE-CYC1-LacZ contain a single ERE or three glucocorticoid response elements (GREs) upstream of a truncated *CYC1* promoter linked to the  $\beta$ -galactosidase gene; these plasmids also contain the *URA3* gene as a selectable marker and the yeast 2 $\mu$ m plasmid replication origin. Full-length GRP1 was expressed constitutively in yeast from the alcohol dehydrogenase promoter as described previously (21).

**Transient transfections.** MCF-7 cells were seeded onto 60-mm dishes at 2.5  $\times$  10<sup>5</sup> cells/dish in phenol red-free Dulbecco modified Eagle medium supplemented with 10% charcoal-stripped fetal bovine serum. The following day the cells were transfected by the liposome-mediated method as described by the manufacturer (Trans IT-100; Pan Vera, Madison, Wis.) with 5  $\mu$ g of ERE-thymidine kinase-luciferase reporter plasmid (XETL) and 2  $\mu$ g of pCMV-HA-p23. At 12 h posttransfection, cells were refed with the same medium containing 0.1 nM 17 $\beta$ -estradiol or ethanol vehicle. A luciferase assay was performed 24 h later as previously described (50).

**$\beta$ -Galactosidase assays.** With yeast liquid cultures, quantitative  $\beta$ -galactosidase measurements were carried out as previously described (18). Cultures were grown overnight in selective media containing 2% glucose. Equal numbers of cells (as determined by measuring the optical density at 600 nm [OD<sub>600</sub>]) were pelleted and washed in sterile water to remove glucose medium and subcultured into 2 ml of selective medium containing either 2% galactose–1% raffinose or 2% raffinose. Steroid hormones were added to the medium as a 1,000-fold dilution

in ethanol. Cultures were incubated for 12 h at 30°C. One-half of the cells were pelleted, washed in 0.5 ml of LacZ buffer (5 mM KCl, 0.5 mM MgSO<sub>4</sub> · 7H<sub>2</sub>O, 60 mM Na<sub>2</sub>HPO<sub>4</sub> · 7H<sub>2</sub>O, 60 mM NaH<sub>2</sub>PO<sub>4</sub> · H<sub>2</sub>O [pH 7.0], with 0.025%  $\beta$ -mercaptoethanol added freshly), and pelleted again. Cells were resuspended in 50  $\mu$ l of LacZ buffer and permeabilized by adding 50  $\mu$ l of CHCl<sub>3</sub>–20  $\mu$ l of 0.1% sodium dodecyl sulfate (SDS) and vortexing for 10 s. After 5 min, 0.5 ml of a 2-mg/ml concentration of *o*-nitrophenyl- $\beta$ -D-galactopyranoside (ONPG) was added, and the reaction was allowed to continue for 1 to 10 min, after which the reaction was stopped by adding 0.5 ml of 1 M Na<sub>2</sub>CO<sub>3</sub>. Reactions were centrifuged for 1 min to pellet the cell debris, and levels of  $\beta$ -galactosidase activity were determined by measuring the OD<sub>420</sub>. The cell number was determined by measuring the OD<sub>600</sub> of the remaining cells. Receptor activity is expressed as  $\beta$ -galactosidase units, determined by using the following equation:  $\beta$ -galactosidase units = (1,000  $\times$  OD<sub>420</sub>)/(reaction volume [milliliters]  $\times$  reaction time [minutes]  $\times$  OD<sub>600</sub>). All experiments were performed in triplicate, and the data shown are representative of multiple experiments. The experiments were performed in the linear range of the assay.

Plate assays were performed by replica plating colonies from glucose plates onto galactose X-Gal (5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside) indicator plates containing 1 mM 17 $\beta$ -estradiol.

**Preparation of yeast extracts and immunoblotting.** Yeast extracts were prepared from 5-ml cultures. Equal numbers of cells (as determined by measuring the OD<sub>600</sub>) were pelleted and washed in 0.5 ml of 1 $\times$  phosphate-buffered saline (PBS) supplemented with 3 mM dithiothreitol and protease inhibitors, including 1 mM phenylmethylsulfonyl fluoride and 1  $\mu$ g each of aprotinin, pepstatin A, and leupeptin per ml. Subsequent steps were carried out at 4°C. Cells were again pelleted and resuspended in 200  $\mu$ l of receptor buffer (10 mM Tris, pH 7.5; 1 mM EDTA; 50 mM NaCl; 20% glycerol) containing protease inhibitors. An equal volume of glass beads was added to each tube, and cells were lysed by shaking for 20 min in an Eppendorf horizontal shaker. Extracts were separated from glass beads by centrifuging the extracts through a small hole (made with a 20-gauge needle) at the bottom of the microfuge tube. The lysates were subsequently cleared by centrifugation at 10,000 rpm for 15 min, after which the supernatants were transferred to a new tube. The protein concentration of each extract was measured by using the Bio-Rad Protein Assay and then standardized accordingly. For Western blotting, protein extracts (50 to 100  $\mu$ g) were fractionated on SDS–10% polyacrylamide gels and transferred to Immobilon paper (Millipore). Blots were probed either with a combination of the ER monoclonal antibodies C311 and C314 (Santa Cruz) or with the anti-HA monoclonal antibody 12CA5 (Boehringer Mannheim). Rabbit polyclonal antiserum against endogenous yhp23 was the generous gift of B. Freeman (University of California at San Francisco). The blots were developed with horseradish peroxidase-coupled sheep anti-mouse or donkey anti-rabbit antibodies and enhanced chemiluminescence reagent (Amersham).

**In vivo estradiol-binding assay.** Ligand-binding assays were carried out as previously described (34). Duplicate cultures of yeast cells containing either G400V ER with or without HA-yhp23 or wt ER with or without HA-yhp23 were inoculated into selective liquid medium containing 2% galactose–1% raffinose and grown overnight at 30°C to induce receptor expression. Equal numbers of cells were pelleted and inoculated into 3 ml of 2% galactose–1% raffinose medium containing either 1 nM (G400V ER) or 0.1 nM (wt ER) of <sup>3</sup>H-labeled 17 $\beta$ -estradiol (72 Ci/mmol) (NET317; NEN) such that the final OD<sub>600</sub> was 2. Cells were incubated with the labeled estradiol for 1 h at 30°C, after which 1 ml of the cultures was pelleted and washed three times with 2% glucose in PBS, resuspended in 150  $\mu$ l of the same solution, and then transferred to a scintillation vial. After the addition of scintillation fluid, the total <sup>3</sup>H-labeled 17 $\beta$ -estradiol was measured by scintillation counting. To account for any nonspecific binding, <sup>3</sup>H-labeled 17 $\beta$ -estradiol binding to a GR-containing strain was subtracted from the counts obtained with the ER-expressing strain.  $\beta$ -Galactosidase assays were carried out as described above with 1 ml of the remaining culture.

**Subcellular localization of yhp23.** W303a was transformed with the pRS314<sub>GPD</sub>-yhp23-GFP expression vector; with the ERE-dependent  $\beta$ -galactosidase reporter plasmid; or with the p2H GAL expression vector containing G400V ER, wt ER, GR, or p2H GAL plasmid alone. Yeast strains were grown in 2 ml of 2% galactose–1% raffinose for 12 h. Cells were fixed by adding 240  $\mu$ l of 37% formaldehyde to each 2-ml culture and incubated at 30°C for 90 min. Cultures were then pelleted by centrifugation and washed three times with 200  $\mu$ l of solution A (1.2 M sorbitol, 50 mM KPO<sub>4</sub>). Cell walls were digested by resuspending cells in 100  $\mu$ l of solution A plus 0.1%  $\beta$ -mercaptoethanol, 0.02% Glusulase (Dupont), and 5  $\mu$ g of Zymolase (U.S. Biological) per ml for 1 h at 37°C. Cells were then washed twice in 100  $\mu$ l of PBS and once in 100  $\mu$ l of PBS plus 0.1% Nonidet P-40 (NP-40) and then blocked for 2 h in 5% bovine serum albumin in Tris-buffered saline (pH 7.4) at room temperature. Cells were then incubated with 100  $\mu$ l of the appropriate anti-steroid receptor primary antibody (for ER, a mixture of monoclonal antibodies C311 and C314 [Santa Cruz], and for GR, monoclonal antibody BuGr2 diluted in blocking solution) for 2 h at room temperature. Cells were washed once in 100  $\mu$ l of PBS, once in 100  $\mu$ l of PBS plus 0.1% NP-40, and once again in 100  $\mu$ l of PBS, followed by incubation with goat anti-mouse rhodamine-conjugated secondary antibody (Vector Labs), diluted in blocking solution, for 4 h at room temperature. Secondary antibody was removed by washing the cells twice in 100  $\mu$ l of PBS and then twice in 100  $\mu$ l of PBS plus 0.1% NP-40. In order to visualize the nuclei, cells were then incubated




FIG. 1. Isolation of a yeast genomic fragment that suppresses the G400V ER phenotype. (A) Transcriptional activity of wt ER and G400V ER as a function of 17- $\beta$ -estradiol concentration. The W303a yeast strain was transformed with a galactose-inducible expression vector containing either wt or G400V ER, along with an ERE-containing  $\beta$ -galactosidase reporter plasmid. Transcriptional activation by wt ER (solid circles) and G400V ER (open circles) in response to increasing 17- $\beta$ -estradiol concentration was determined by liquid  $\beta$ -galactosidase assay as described in Materials and Methods. Note that G400V ER requires a 100-fold-higher estradiol concentration to induce transcriptional activation than wt ER. The dosage suppression screen was carried out in the presence of 1 nM 17- $\beta$ -estradiol, the conditions under which the G400V ER phenotype is most pronounced. (B) The relative activity of wt ER, G400V ER, and G400V ER plus suppressor 4.3. Four independent colonies on X-Gal indicator plates containing 1 nM 17- $\beta$ -estradiol are shown and represent wt ER plus empty library plasmid (wt ER), G400V ER plus empty library plasmid (G400V ER), or G400V ER plus suppressor plasmid 4.3 (G400V ER+4.3). (C) Transcriptional activity of wt ER, G400V ER, and G400V ER in the presence of suppressor 4.3. Liquid  $\beta$ -galactosidase assays were performed on yeast strains containing wt ER plus empty library plasmid, G400V ER plus empty library plasmid, or G400V ER plus 4.3 at 1 nM 17- $\beta$ -estradiol. Suppressor 4.3 increases G400V ER activity 10-fold, bringing its activity to nearly one-third that of wt ER. (D) Identification of YKL117w as the G400V ER suppressor. The sequence of the yeast genomic fragment contained within the suppressor 4.3 was determined by aligning the 5' and 3' ends of the insert to the yeast genomic sequence database. Suppressor 4.3 contains an 8,147-bp fragment comprising four complete ORFs (YKL121w, PMT1, VPH2, and YKL117w), a partial ORF (YKL116w), and a tRNA-Ala gene (shaded box). The relative positions and orientations of the genes within the 4.3 fragment are shown schematically (fragment 1). Identification of the gene responsible for suppressing the G400V ER phenotype was accomplished by constructing 5' and 3' deletion derivatives of the 4.3 suppressor (fragments 2 to 5) and assaying their ability to increase G400V ER transcriptional activity at 1 nM 17- $\beta$ -estradiol. "yes" indicates that the fragment was capable of suppressing the G400V ER phenotype; "no" indicates that the fragment failed to increase G400V ER transcriptional activity. YKL117w was present within the suppressing fragments (fragments 1 to 4) but was absent within the fragment that did not suppress (fragment 5), suggesting that its gene product is responsible for increasing G400V ER transcriptional activation. YKL117w encodes the yeast homologue of the human p23 protein (yhp23).

in 1  $\mu$ g of Hoechst dye H334211 per ml for 10 min, followed by one wash with 100  $\mu$ l of PBS. Cells were then resuspended in 30  $\mu$ l of PBS, 5  $\mu$ l of which was then plated onto a poly-D-lysine-treated microscope slide and allowed to settle for 10 min before excess fluid was removed by aspiration. Unattached cells were then removed by washing the slide with 20  $\mu$ l of PBS. The cells were mounted by using 3  $\mu$ l of Citifluor (Ted Pella, Reading, Calif.), and a coverslip was secured to the slide with rubber cement. GFP, rhodamine, and Hoechst signals were imaged and photographed by using a Zeiss Axioplan 2 microscope.

## RESULTS

**Yeast dosage suppression screen.** To compare wt ER and G400V ER function in yeast cells, we constructed two strains containing a galactose-inducible expression vector, encoding either wt ER or G400V ER, and a reporter plasmid containing an ERE located upstream of the  $\beta$ -galactosidase gene. The transcriptional activities of wt ER and G400V ER, as a function of hormone concentration, were measured. Compared to wt ER, G400V ER requires a 100-fold increase in 17- $\beta$ -estra-

diol concentration before receptor transcriptional activation is observed in our yeast assay (Fig. 1A). At saturating ligand concentrations, however, G400V ER is able to reach the same maximal activity as wt ER, suggesting that once the block to steroid binding is overcome, the receptor is able to act as efficiently as wt ER in entering the functional interactions downstream of estradiol binding, including both protein-protein and protein-DNA interactions, that are necessary for transcriptional activation.

The G400V ER phenotype is most apparent at a concentration of 1 nM 17- $\beta$ -estradiol, where wt ER shows maximal transcriptional response, but G400V ER displays only minimal transcriptional activity (Fig. 1A). Exploiting this phenotypic difference, we carried out a dosage suppression screen to identify yeast proteins that, when overexpressed, would increase the transcriptional activity of G400V ER, thereby suppressing the mutant phenotype. The yeast strain containing G400V ER

and an estrogen-responsive  $\beta$ -galactosidase reporter gene was transformed with a high-copy-number yeast genomic library and assayed for G400V ER transcriptional activity on X-Gal indicator plates containing 1 nM 17- $\beta$ -estradiol. Under these conditions, yeast colonies expressing the wt ER are blue, while the G400V ER-expressing yeast colonies appear white (Fig. 1B). Blue colonies were considered to be potential suppressor candidates. Five candidate suppressors of the G400V ER phenotype were isolated after screening ~6,000 colonies, which we estimate to represent about one-half of the yeast genome.

**Identification of the yeast ORF YKL117w as a suppressor of the G400V ER phenotype.** One high-copy-number suppressor plasmid, designated 4.3, was found to increase G400V ER transcriptional activity 10-fold, bringing G400V ER transcriptional activation to one-third the wt ER level at 1 nM 17- $\beta$ -estradiol (Fig. 1B and C). The 5' and 3' ends of the insert of the library plasmid were sequenced and aligned with the yeast genome. In this manner, we were able to identify the suppressor DNA as an 8,147-bp genomic fragment of chromosome XI (26) containing multiple open reading frames (ORFs) (Fig. 1D). To identify the suppressing ORF, a series of deletions were constructed and analyzed for their ability to increase G400V ER transcriptional activity. As seen in Fig. 1D, the suppression of the G400V ER phenotype correlates with the presence of ORF YKL117w.

**Possible role of YKL117w in ER signaling.** A search of the Swissprot database revealed YKL117w to be the yeast homologue of the human p23 protein (yhp23) (28), a component of the Hsp90-based molecular chaperone complex. During completion of this study, two separate reports (2, 16) characterizing yeast strains with YKL117w deleted have called this gene *SBA1*, reflecting an increased susceptibility of steroid signaling to benzoquinone ansamycin antibiotics. Since the YKL117w gene product's homology to the vertebrate p23 protein was of considerable importance in investigating its role in ER function, we have chosen to refer to it as yhp23 to maintain this emphasis.

Although p23's specific function is not known, *in vitro* studies suggest that it is crucial to the stability of the aporeceptor complex of unliganded steroid receptors. Removal of p23 greatly reduces the formation of stable aporeceptor complexes of the GR (11, 12, 24) and the progesterone receptor (PR) (29, 30). In addition, *in vitro* studies have suggested that p23 possesses abilities typical of molecular chaperones, since it is capable of interacting with denatured  $\beta$ -galactosidase, suppressing its aggregation and maintaining it in an intermediate, folding-competent conformation (17). The relative importance of these two aspects of p23 function in ER signaling has not been determined.

**Characterization of yhp23's role in ER signaling.** Having identified yhp23 as the suppressing ORF, we cloned the YKL117w gene with an amino-terminal HA epitope tag (HA-yhp23) into a yeast expression vector containing a constitutively active GPD promoter. We then established a yeast strain that overexpresses HA-yhp23 in the presence of G400V ER, along with a reporter plasmid containing the  $\beta$ -galactosidase gene under control of an ERE. As seen in Fig. 2A, overexpression of HA-yhp23 increases G400V ER transcriptional activity by 10-fold. Extracts from these yeast strains were prepared and analyzed by immunoblotting with antibodies specific for ER and HA. Figure 2B demonstrates that the overexpression of yhp23 does not affect the level of G400V ER protein and, therefore, the increase in transcriptional activity is not a result of increased receptor expression. The HA-tagged yhp23 protein migrates on an SDS-polyacrylamide gel at approximately 34 kDa. The higher molecular mass of the yeast protein (34 kDa versus the 23-kDa human protein) is expected, as the

yhp23 is larger (216 residues) than its human counterpart (160 residues). Further comparison of G400V ER activity in the presence or absence of yhp23 overexpression over a range of hormone concentrations revealed that G400V ER function was also enhanced at 10 nM 17- $\beta$ -estradiol (Fig. 2C). The 30% increase in G400V ER activity seen at this level of hormone, however, is relatively small compared to the 10-fold increase observed at the 1 nM 17- $\beta$ -estradiol concentration used in the screen. This pattern continues at even higher hormone concentrations, so that no increase of G400V ER activity by yhp23 is observed at 100 nM concentrations of 17- $\beta$ -estradiol (Fig. 2C) and 1 mM 17- $\beta$ -estradiol (data not shown). These findings suggest that yhp23's importance to G400V ER signaling decreases at high estradiol concentrations.

Given p23's proposed chaperone-like activities *in vitro*, it could be argued that yhp23's interaction with the mutant G400V ER might arise as a function of the receptor's misfolded steroid-binding domain rather than reflect a true role in the ER signaling pathway. To determine whether yhp23 overexpression affects wt ER activity, we constructed an additional yeast strain that overexpresses yhp23 in the presence of wt ER, along with an ERE-controlled  $\beta$ -galactosidase gene reporter plasmid. The effect of yhp23 overexpression upon ER activity was then assayed over a range of hormone concentrations (Fig. 2D). wt ER activity was affected in a manner similar to that of G400V ER, albeit less dramatically. At 0.1 nM 17- $\beta$ -estradiol, wt ER activity is increased by approximately 70% in the presence of overexpressed yhp23, with no increase observed at the higher concentrations of 1 and 10 nM 17- $\beta$ -estradiol. In contrast to G400V ER, however, an increase in wt ER activity was observed at 0.01 nM 17- $\beta$ -estradiol. To more closely examine the effect of yhp23 on wt ER activity at this low hormone concentration, we compared wt ER ligand-independent activity to wt ER activity at 0.01 nM 17- $\beta$ -estradiol. As seen in Fig. 2E, overexpression of yhp23 increases wt ER ligand-independent activity by approximately twofold and ligand-dependent activation by threefold in the presence of 0.01 nM 17- $\beta$ -estradiol. These findings suggest that overexpression of yhp23 greatly increases wt ER's ability to respond to low levels of ligand. Without yhp23 overexpression, the fold induction of wt ER activity was only 50% upon administration of 0.01 nM 17- $\beta$ -estradiol compared to a 250% induction of wt ER activity in the presence of overexpressed yhp23. These results suggest that increased levels of yhp23 can facilitate wt ER ligand-independent activity and potentiate ER signaling at low levels of hormone. Thus, the ability of yhp23 to functionally interact with wt ER and not just the G400V ER mutant strongly implicates yhp23 as a member of the ER signaling pathway in yeast cells.

Importantly, yhp23 does not appear to have any effect upon the activity of the ER AF-1 domain. When we fused the amino-terminal 115 residues of ER to a Lex DNA binding domain and expressed this construct in yeast cells, we observed constitutive activation of a Lex-responsive  $\beta$ -galactosidase reporter plasmid, a result consistent with earlier findings demonstrating that the AF-1 activity of ER is contained within this region of the receptor (39). As shown in Fig. 2F, this constitutive activation was not affected by yhp23 overexpression, suggesting that the increased function of both the mutant and the wt ER observed in Fig. 2C and D, respectively, does not appear to be mediated by an increase in AF-1 activity. This finding, taken together with the observed hormone concentration-dependent effect of yhp23 overexpression (Fig. 2C and D), suggests that yhp23 affects the ER signal transduction pathway at the step of ligand binding.




FIG. 2. Effect of yhp23 overexpression on G400V ER and wt ER transcriptional activity. An HA-tagged yhp23 gene was cloned into the yeast expression vector pRS314 downstream of the GPD promoter. Yeast strains were then constructed which coexpress G400V ER or wt ER with the HA-tagged yhp23 in the presence of a  $\beta$ -galactosidase reporter gene under the control of the appropriate hormone response element (ERE). (A) Overexpression of HA-yhp23 increases G400V ER transcriptional activation. The activity of G400V ER in the presence or absence of overexpressed yhp23 was determined by liquid  $\beta$ -galactosidase assay at a 1 nM concentration of 17- $\beta$ -estradiol. Overexpression of yhp23 increased G400V ER activity approximately 10-fold. (B) Increased transcriptional activation of G400V ER by yhp23 is not a function of increased ER levels. Whole-cell lysates were prepared from the yeast strains described in panel A. Equal amounts of proteins were separated on an SDS-4 to 20% gradient polyacrylamide gel, transferred to Immobilon paper, and probed with an ER-specific monoclonal antiserum (top panel) or a monoclonal antibody directed against the HA epitope on yhp23 (bottom panel) and visualized by enhanced chemiluminescence. (C) Dose-response curves for G400V ER. The activity of G400V ER in the absence (open circles) or presence (solid circles) of overexpressed yhp23 at the indicated 17- $\beta$ -estradiol concentrations is shown. The increased transcriptional activity displayed by G400V ER in the presence of HA-yhp23 overexpression is seen to be greatest at low hormone concentrations and is lost completely at the highest hormone concentrations assayed. (D) Dose-response curves for wt ER. The activity of wt ER in the absence (open squares) or presence (solid squares) of overexpressed HA-yhp23 at the indicated 17- $\beta$ -

yhp23 overexpression increases ligand binding by both G400V ER and wt ER. Considering p23's proposed role in aporeceptor complex formation and given the nature of the G400V ER mutation, we examined whether the increase in G400V ER transcription in the presence of overexpressed yhp23 results from increased estradiol binding by the receptor. Estradiol binding by G400V ER and wt ER in the presence or absence of yhp23 overexpression was measured *in vivo*. The yeast strains were incubated for 1 h in medium containing  $^3\text{H}$ -labeled 17- $\beta$ -estradiol and washed three times to remove unbound steroid, and the amount of estradiol bound to G400V ER and wt ER was measured by quantifying the  $^3\text{H}$ -labeled 17- $\beta$ -estradiol content by liquid scintillation counting.  $\beta$ -Galactosidase assays were carried out in parallel on the same cells to correlate effects of ligand binding to transcriptional activation.

We first examined ligand binding by G400V ER at a 1 nM concentration of  $^3\text{H}$ -labeled 17- $\beta$ -estradiol. As seen in Fig. 3A, ligand binding by G400V ER was increased by approximately fivefold in the presence of overexpressed yhp23. This increase in ligand binding was found to correlate with a sevenfold increase in G400V ER transcriptional activity (Fig. 3B). Immunoblot analysis showed that the levels of G400V ER were unchanged by yhp23 overexpression (data not shown).

We then examined ligand binding by wt ER, which was also found to increase in the presence of yhp23 overexpression, although to a lesser extent. At a 0.1 nM concentration of  $^3\text{H}$ -labeled 17- $\beta$ -estradiol, wt ER ligand binding was increased by approximately 50% (Fig. 3C).  $\beta$ -Galactosidase assay of these cells demonstrated a corresponding 70% increase in transcriptional activity (Fig. 3D). Again, immunoblot analysis showed no difference in the level of ER expression exhibited by the two strains (data not shown). These results indicate that yhp23 overexpression increases ER transcriptional activity by increasing the total number of ligand-bound receptors.

The magnitude of yhp23's effect on wt ER signaling is a function of wt ER and estradiol concentrations. Having demonstrated that overexpression of yhp23 increases wt ER transcriptional activity, we next asked whether a decrease in yhp23 concentration would reduce wt ER activity. To this end, we compared wt ER transcriptional activity in the yhp23 knockout strain (KO) to that in the parental strain (PA) (2), as well as the parental strain overexpressing HA-yhp23 (PA+HA-yhp23 strain). In this way, we were able to assay wt ER function (i) in the absence of yhp23 (KO), (ii) in the presence of endogenous levels of yhp23 (PA), and (iii) in the presence of both endogenous yhp23 and overexpressed HA-yhp23 (PA+HA-yhp23) (Fig. 4B). A wt ER expression vector and an ERE- $\beta$ -galactosidase reporter plasmid were introduced into these three yeast strains, and wt ER transcriptional activity was assayed at 0.1 nM 17- $\beta$ -estradiol. The activity of wt ER within the three different strains at this hormone concentration is shown in Fig.

estradiol concentrations is shown. The effect of HA-yhp23 overexpression is seen to be greatest at low hormone concentrations and is lost completely at the highest hormone concentrations assayed. (E) Overexpression of HA-yhp23 increases the ligand-independent activity of the ER. The activity of the ER in the absence or presence of 0.01 nM 17- $\beta$ -estradiol is shown. Ligand-independent transcriptional activity by ER is approximately threefold higher in the presence of HA-yhp23 overexpression. The addition of 0.01 nM 17- $\beta$ -estradiol resulted in a greater level of ER ligand-dependent activity in the HA-yhp23 overexpressing strain, suggesting that yhp23 overexpression increases the sensitivity of ER to low concentrations of 17- $\beta$ -estradiol. (F) HA-yhp23 overexpression does not affect the AF-1 activity of ER. The amino-terminal 115 residues of ER, containing the AF-1 activity of the ER in yeast cells, were fused to a Lex DNA binding domain (see Materials and Methods). Constitutive AF-1 activity resulted in transcription of a reporter  $\beta$ -galactosidase gene downstream of a LexA binding site, which was unaffected by overexpression of HA-yhp23.




FIG. 3. Overexpression of yhp23 increases estradiol binding by G400V ER and wt ER in vivo. The total amount of estradiol bound by G400V ER and wt ER in the binding or absence of yhp23 overexpression was determined by an *in vivo* ligand-binding assay with the same yeast strains as described in Fig. 2. After a 1-h incubation in the presence of  $^3\text{H}$ -labeled 17- $\beta$ -estradiol, cells were washed to remove unbound ligand, and the amount of bound estradiol was determined by liquid scintillation counting. Liquid  $\beta$ -galactosidase assays were carried out, in parallel, on an aliquot of the same  $^3\text{H}$ -labeled 17- $\beta$ -estradiol-incubated cells in order to correlate the levels of ligand binding to the resulting levels of transcriptional activation. Whole-cell extracts from the assayed yeast strains were fractionated on SDS-polyacrylamide gel electrophoresis, and ER expression was examined by use of immunoblotting with an ER-specific rabbit polyclonal antiserum as described in Materials and Methods. No alteration in G400V ER or wt ER levels in response to increased HA-yhp23 expression were noted (data not shown). (A) HA-yhp23 overexpression increases ligand binding by G400V ER. Cells expressing G400V ER in the presence or absence of HA-yhp23 overexpression were assayed for ligand binding in the presence of 1 nM  $^3\text{H}$ -labeled 17- $\beta$ -estradiol. Ligand binding by G400V ER is seen to increase approximately fivefold in the presence of overexpressed HA-yhp23. (B) Increased ligand binding by G400V ER in the presence of HA-yhp23 overexpression correlates with an increase in transcriptional activation by the receptor. Liquid  $\beta$ -galactosidase assays, carried out on an aliquot of the cells described in panel A, demonstrate a corresponding sevenfold increase in transcriptional activity by G400V ER. (C) HA-yhp23 overexpression increases ligand binding by wt ER. Cells expressing wt ER in the presence or absence of HA-yhp23 overexpression were assayed for ligand binding in the presence of 0.1 nM  $^3\text{H}$ -labeled 17- $\beta$ -estradiol. Ligand binding by wt ER is seen to increase by approximately 50% in the presence of overexpressed HA-yhp23. (D) Increased ligand binding by wt ER in the presence of HA-yhp23 overexpression correlates with an increase in transcriptional activation by the receptor. Liquid  $\beta$ -galactosidase assays, carried out on an aliquot of the cells described in panel C, demonstrate a corresponding 70% increase in transcriptional activity by wt ER.

4A. In the absence of yhp23 (KO), wt ER signaling still occurs, demonstrating that wt ER is capable of functioning in a yhp23-independent manner. Endogenous levels of yhp23 (PA) result in a 50% increase in wt ER activity relative to the KO strain. The PA+HA-yhp23 strain, which contains the highest yhp23 levels (Fig. 4B), exhibits an even higher level of wt ER induction (2.7-fold) than that seen in the KO strain. This increase in




FIG. 4. Yhp23's effect on wt ER activity is a function of the yhp23, ER, and estradiol concentrations. wt ER transcriptional activation was compared in three yeast strains expressing yhp23 at different concentrations. The knockout strain (KO) is yhp23 deficient, the parental strain (PA) expresses yhp23 at endogenous levels, and the HA-yhp23-transformed parental strain (PA+HA-yhp23) expresses endogenous yhp23 and exogenous HA-yhp23. All three strains express wt ER under the control of a galactose-inducible promoter, along with an ERE- $\beta$ -galactosidase reporter plasmid. wt ER activity in the KO and PA+HA-yhp23 strains was compared over a range of hormone concentrations as shown in Fig. 2D. The greatest effect of yhp23 levels was observed at 0.1 nM 17- $\beta$ -estradiol. Data shown represent the results of  $\beta$ -galactosidase assays repeated with all three yeast strains (KO, PA, and PA+HA-yhp23) at this hormone concentration. (A) The effect of yhp23 on wt ER transcriptional activation at high ER concentrations. ER transcriptional activity as a function of yhp23 concentration was determined by liquid  $\beta$ -galactosidase assay in cells incubated in galactose-raf- inose-supplemented medium containing 0.1 nM 17- $\beta$ -estradiol. (B) KO, PA, and PA+HA-yhp23 strains express different levels of yhp23. Equal amounts of whole-cell lysates from the KO, PA, and PA+HA-yhp23 strains were analyzed by immunoblotting by using anti-yhp23 polyclonal antibody as described in Materials and Methods. The upper band seen in the PA+HA-yhp23 lane corresponds to the HA-tagged yhp23. (C) The effect of yhp23 on wt ER transcriptional activity at low wt ER concentration. ER transcriptional activity as a function of yhp23 concentration was determined by liquid  $\beta$ -galactosidase assay in cells incubated in raffinose-supplemented medium containing 0.1 nM 17- $\beta$ -estradiol. Under these conditions ER expression is 10-fold lower than with cells grown in the presence of galactose (not shown). (D) yhp23 induction of wt ER transcriptional activity is inversely proportional to wt ER concentration. The fold induction of yhp23 on ER transcriptional activity at 0.1 nM 17- $\beta$ -estradiol under conditions of high ER expression (galactose; shaded columns) or low ER expression (raffinose; solid columns) is standardized to the ER activity in the KO strain. (E) The effect of yhp23 on wt ER function is inversely proportional to the ligand concentration. The fold induction of ER transcriptional activation in the PA+HA-yhp23 versus KO strains at 0.1 and 1 nM 17- $\beta$ -estradiol was determined under conditions of low ER expression (raffinose medium). The results indicate that the fold induction of ER transcriptional activation in the presence of yhp23 overexpression is significantly greater at 0.1 nM 17- $\beta$ -estradiol than at 1 nM 17- $\beta$ -estradiol. (F) yhp23 overexpression increases estradiol-independent wt ER transcriptional activation. The effect of yhp23 overexpression on ERE-dependent transcriptional activation in the presence or absence of ER is shown. KO and PA+HA-yhp23 strains containing the ERE reporter construct were transformed with either the empty expression vector or with the ER-containing expression vector and assayed for  $\beta$ -galactosidase activity in galactose-raf- inose medium without estradiol.



wt ER activity is not a function of increased receptor levels, since wt ER levels were unchanged in the absence or presence of yhp23 (data not shown). Thus, wt ER transcriptional activity increases in direct proportion to the concentration of yhp23.

Having shown that wt ER activity increases as a function of yhp23 concentration, we next asked if the effect of yhp23 upon ER signaling is also a function of wt ER concentration. This was accomplished by repeating the above experiment in medium containing only raffinose as a carbon source, resulting in low levels of wt ER expression. When wt ER transcriptional activity was assayed under these conditions, a similar pattern of yhp23-dependent ER activation was observed: wt ER functions in the KO strain, and this activity increases as a function of yhp23 concentration (Fig. 4C). Importantly, the magnitude of the effect of yhp23 on wt ER transcriptional activation is greater at the lower wt ER concentration, such that overexpression of the yhp23 in the PA+HA-yhp23 strain results in an almost fivefold increase in wt ER transcriptional activity relative to the KO strain, thereby doubling the induction seen at high wt ER concentrations (Fig. 4D). Thus, the magnitude of yhp23's effect on wt ER transcriptional activity is greater at low, rather than high, wt ER concentrations.

Our earlier studies of yhp23 induction of G400V ER and wt ER activity (Fig. 2C and D) suggested that the importance of yhp23 to wt ER function correlates inversely to hormone concentration. This idea was further confirmed with the KO and PA+HA-yhp23 strains, when the activity of wt ER within these strains was assayed at both 0.1 and 1 nM 17- $\beta$ -estradiol under conditions of low wt ER expression. As seen in Fig. 4E, the fivefold induction of wt ER transcriptional activity observed within the PA+HA-yhp23 strain at 0.1 nM 17- $\beta$ -estradiol decreases to only a twofold induction at the higher concentration of 1 nM 17- $\beta$ -estradiol. Again this trend continues such that, when activities are compared at yet higher hormone concentrations, no difference in activity is observed between the KO and PA+HA-yhp23 strains at 10 nM 17- $\beta$ -estradiol (data not shown). Thus, the effect of yhp23 overexpression on wt ER transcriptional activation is inversely proportional to the hormone concentration.

Comparison of wt ER activity in the KO and PA+HA-yhp23 strains in the absence of estradiol again confirmed a role for yhp23 in wt ER ligand-independent transcriptional activation. As shown in Fig. 4F, yhp23 is not essential to wt ER-dependent activation in the absence of ligand. Interestingly, as was observed with ligand-dependent activity, wt ER function in the absence of ligand increases with yhp23 overexpression. This effect on transcription is not observed in the absence of wt ER expression, suggesting that yhp23 is operating via wt ER to induce estradiol-independent transcriptional activation.

Thus, the relationship of yhp23 to wt ER signal transduction is dependent not only on concentrations of yhp23 but also upon the levels of wt ER and estradiols. Our data demonstrate that the effect of yhp23 upon wt ER function is most pronounced when wt ER activity is examined at low estradiol and wt ER concentrations.

**yhp23 is not essential for the formation of a functional ER-GRIP1 complex.** The ER activates transcription in mammalian cells through two transcriptional activation domains, termed AF-1 and AF-2 (36). The AF-1 domain, located within the amino terminus of the receptor, does not require steroid binding to achieve an active conformation (39). In contrast, the AF-2 domain lies within the steroid-binding domain and is dependent upon estradiol binding for its activity (55). The ER AF-2 region has been shown to activate transcription in yeast cells and in cultured mammalian cells through interaction with coactivator proteins, including GRIP1/TIF2 (21) and SRC1




FIG. 5. yhp23 is not essential for the functional interaction between ER and the coactivator GRIP1. yhp23 KO and PA strains were constructed that express wt ER both in the presence or in the absence of the coactivator GRIP1. ER activity was assayed in the four strains after incubation in raffinose medium containing 0.1 nM 17- $\beta$ -estradiol. Data were collected in the same experiment but are displayed with separate y axes to more clearly demonstrate GRIP1 induction of ER activity within each strain. Coexpression of GRIP1 increases ER transcriptional activation in both KO and PA strains approximately 10-fold, an effect that is independent of yhp23 expression. Note that yhp23 increased ER transcriptional activation to the same extent in the absence or presence of GRIP1.

(43). Although AF-2 activity is observed in some promoter contexts in yeast cells (40), the AF-2 coactivators have no yeast homologues, and thus ER transcriptional activity in yeast cells is greatly potentiated in the presence of ectopically expressed mammalian coactivators (22). We therefore sought to more specifically determine whether yhp23 might play a role in AF-2-coactivator interactions.

The recent determination of the structure of the ER ligand-binding domain bound to estradiol has suggested that proper folding of this region around the steroid hormone is crucial to the formation of an AF-2 domain competent for interaction with coactivators (3). Since p23 has been proposed to have chaperone-like activities (17), we hypothesized that it may play a role in the proper folding of the AF-2 domain around estradiol during the process of steroid binding. To determine whether yhp23 facilitates wt ER AF-2-coactivator interactions, we introduced the mammalian coactivator GRIP1 into yhp23 KO and PA yeast strains expressing wt ER (KO+GRIP1 and PA+GRIP1, respectively). Coexpression of GRIP1 should activate AF-2, thereby increasing wt ER transcriptional activation relative to the control strains lacking GRIP1 (22) and allowing us to compare GRIP1 induction of wt ER activity in the presence or absence of yhp23. If yhp23 were important for AF-2 interaction with GRIP1, then GRIP1-dependent ER transcriptional activation would be reduced in the KO versus the PA strain. However, as shown in Fig. 5, this is not the case. wt ER transcriptional activation in the PA and KO strains is enhanced to similar extents (approximately 10-fold) compared to the corresponding control strains lacking GRIP1 (Fig. 5). Thus, GRIP1 induction of wt ER transcriptional activation is not altered by yhp23 expression, suggesting that yhp23 is not required for the formation of a functional ER-GRIP1 complex.

**ER and yhp23 colocalize within the nucleus of yeast cells.** Prior genetic and biochemical studies have demonstrated that aporeceptor complex formation is conserved in yeast cells (5). Hsp82, the yeast homologue of Hsp90, has been shown to associate with hormone-free ER and GR in yeast cells. In addition, genetic studies indicate that ER and GR signaling is




FIG. 6. ER and yhp23-GFP colocalize within the nucleus of yeast cells. To examine yhp23 subcellular localization in yeast cells, a yhp23-GFP fusion protein was constructed. Yeast strains were created that express yhp23-GFP (A) or GFP (C) either alone or in combination with G400V ER (B and C), wt ER (D and E), or GR (F). Cells were grown in galactose-raffinose-containing medium in the absence or the presence of 17- $\beta$ -estradiol. Cells were fixed, permeabilized, and incubated with the appropriate receptor primary antibody, a corresponding Texas-red-conjugated secondary antibody, and the DNA in the nucleus was stained with Hoechst dye H334211. The GFP, Texas red, and Hoechst fluorescent signals were visualized by using a Zeiss Axioplan 2 fluorescence microscope. Note that yhp23-GFP is expressed throughout the cytoplasm in the absence of ER expression. In the presence of coexpressed G400V ER as well as wt ER, yhp23-GFP becomes localized to the nucleus. Incubation of the wt ER strain in 1  $\mu$ M 17- $\beta$ -estradiol results in the redistribution of yhp23-GFP from the nucleus to the cytoplasm, thereby reversing the ER-yhp23-GFP colocalization observed in the absence of estradiol.  $\alpha$ -S.R., anti-steroid receptor primary antibody.

reduced in yeast strains expressing only 5% of the wt level of Hsp82 (44). Compelling genetic evidence also exists for the role of the yeast Hsp70 (31), p60 (8), Hsp40 (31), and immunophilin (14) homologues in steroid signaling in yeast cells, with the majority of these proteins having been shown to associate with GR in the absence of hormone (2, 7).

Given human p23's presence in the aporeceptor complexes of PR (28) and GR (11) and having shown that yhp23 affects ER function, we proceeded to determine whether yhp23 and ER colocalize in vivo. To determine the cellular distribution of yhp23 in yeast cells, we created a yhp23-GFP fusion protein by subcloning GFP at the carboxy terminus of the yhp23 protein. Expression of the fusion protein was confirmed by Western blotting. Importantly, the yhp23-GFP fusion protein is also able to suppress the G400V ER phenotype (not shown), proving that addition of the GFP moiety does not eliminate yhp23's ability to functionally interact with G400V ER.

We constructed several yeast strains that express yhp23-GFP either alone or in combination with G400V ER, wt ER, or wt GR. Figure 6A demonstrates that the distribution of yhp23-GFP in the absence of steroid receptor expression is largely cytoplasmic, though a small proportion of signal corresponding to the nucleus is also evident. This pattern is consistent with the expression pattern described for the human p23 protein within mammalian cells (28). Strikingly, upon coexpression of G400V ER, yhp23-GFP becomes predominantly limited to the nucleus, thus colocalizing with G400V ER (Fig. 6B). Recall that ER is a steroid receptor that resides in the nucleus in the absence of hormone. Importantly, this pattern of nuclear localization was not seen when G400V ER was coexpressed with just the GFP protein, indicating that yhp23 is responsible for the localization of the fusion protein to the nucleus (Fig. 6C). Nuclear localization of yhp23-GFP was also observed when it

was coexpressed with wt ER (Fig. 6D). Thus, the ability of G400V ER to colocalize yhp23-GFP in the same manner as wt ER suggests that the G400V ER phenotype is not a result of deficient aporeceptor complex formation. Additionally, when cells coexpressing wt ER and yhp23-GFP were incubated in 17- $\beta$ -estradiol, yhp23-GFP redistributed to the cytoplasm, re-establishing the pattern seen in yeast cells lacking ER expression (Fig. 6A). As a final control, yhp23-GFP coexpressed with GR, a steroid receptor that exists outside the nucleus in the steroid-free state, did not localize to the nucleus (Fig. 6F) but instead showed a cytoplasmic distribution similar to that of GR.

The colocalization of yhp23 and ER is consistent with the proposed role of yhp23 as a member of the ER aporeceptor complex. Upon coexpression with ER, aporeceptor complex formation causes yhp23, presumably through an interaction with Hsp82 (the yeast homologue of Hsp90), to become localized to the nucleus. The addition of hormone appears to result in the dissociation of the aporeceptor complex, allowing yhp23 to redistribute throughout the cell.

**Complementation of yhp23 by human p23 in yeast cells.** We next examined whether human p23, when ectopically expressed in yeast cells, functions like yhp23 to suppress the G400V ER phenotype. We established yeast strains that express G400V ER and an ERE-responsive reporter plasmid in the presence of HA-tagged human p23 (HA-p23) or HA-yhp23. A third strain containing the expression vector without an insert (vector) was used as a negative control. As shown in Fig. 7A, human p23 is capable of increasing hormone-dependent G400V ER transcriptional activation in yeast cells, although to a lesser degree than yhp23 (4-fold and 13-fold, respectively). The reduced G400V ER transcriptional activity is not a function of reduced human p23 expression relative to yhp23, since immunoblot analysis with an antibody directed against the HA




FIG. 7. Complementation of *yhp23* by human *p23* in yeast cells. (A) Overexpression of HA-*p23* suppresses the G400V ER phenotype. An HA epitope-tagged human *p23* (HA-*p23*) was subcloned into the yeast expression vector pRS316<sub>GPD</sub>. The W303a yeast strain expressing G400V ER and an ERE- $\beta$ -galactosidase reporter gene was transformed with expression vectors containing no insert (vector), HA-*p23*, or HA-*yhp23*. G400V ER transcriptional activity was measured by liquid  $\beta$ -galactosidase assay in galactose-containing medium with 1 nM 17- $\beta$ -estradiol. Equal amounts of whole-cell lysates from the strain containing vector, HA-*p23*, and HA-*yhp23* were analyzed by immunoblotting by using anti-HA antibody as described in Materials and Methods (bottom panel). (B) Human *p23* partially complements the loss of *yhp23* with respect to ER signaling. *yhp23* KO yeast strain expressing wt ER and an ERE-responsive  $\beta$ -galactosidase reporter gene were transformed with expression vectors containing no insert (vector), HA-*p23*, or HA-*yhp23*. ER transcriptional activity was determined by liquid  $\beta$ -galactosidase assay in raffinose medium containing 0.1 nM 17- $\beta$ -estradiol. Immunoblot analysis for HA-*p23* and HA-*yhp23* was performed as in panel A and demonstrates that HA-*p23* and HA-*yhp23* are expressed at similar levels (bottom panel).

epitope present on both proteins shows equal expression levels in yeast cells (Fig. 7A, bottom panel). In addition, G400V ER expression is unaffected by yeast or human *p23* coexpression (data not shown). These findings suggest that human *p23* can function like *yhp23* in yeast cells, albeit less potently, to increase G400V ER transcriptional activity.

We next evaluated whether human *p23* could function in yeast cells to increase ER transcriptional activation in the absence of endogenous *yhp23*. The KO strain expressing wt ER and an ERE-responsive promoter were transformed with the empty expression vector, HA-*p23*, or HA-*yhp23*. When assayed at a 0.1 nM concentration of 17- $\beta$ -estradiol, expression of human *p23* increases ER transcriptional activity compared to the use of the vector only (Fig. 7B), but to a lesser extent than with *yhp23* (twofold and fivefold, respectively). Again, the reduced activity of ER in the human *p23*-expressing strain is not a function of reduced *p23* levels relative to *yhp23* (Fig. 7B, bottom panel). These findings indicate that human *p23* can partially complement the loss of *yhp23* function in yeast cells with respect to ER signaling, thus suggesting that *yhp23* and *p23* are functional homologues.

**Increased ER transcriptional activation by human *p23* overexpression in MCF-7 cells.** To establish whether *p23* affects ER signal transduction in mammalian cells, we examined the ability of human *p23* to increase ER-mediated transcriptional enhancement when overexpressed in cultured mammalian cells. ER-containing MCF-7 cells were transfected with the reporter plasmid ERE-thymidine kinase-luciferase and a plasmid encoding human *p23*. Transfected cells were treated with 0.1 nM 17- $\beta$ -estradiol or ethanol vehicle for 24 h, and the transcriptional activity was quantified by measuring the luciferase activity. As shown in Fig. 8, both hormone-dependent and hormone-independent ER transcriptional activity are increased roughly twofold when *p23* is overexpressed. This likely represents an underestimate of *p23*'s importance to ER func-




FIG. 8. Activation of ER transcriptional enhancement by *p23* overexpression. ER-containing MCF-7 cells ( $2.5 \times 10^5$  cells/6-cm dish) were transiently transfected by using the lipid Trans-IT 100 with 5  $\mu$ g of the ERE-containing luciferase reporter plasmid and 2  $\mu$ g of a pCMV expression vector (open columns) or pCMV-HA-*p23* expression vector (shaded columns). Cells were incubated for 24 h in the presence of 0.01 nM 17- $\beta$ -estradiol or ethanol vehicle and then harvested. ER transcriptional activation was measured by using a luciferase assay, normalized to total protein concentration in each sample, and expressed as relative luminescence units (RLU). The data represent the mean of an experiment done in triplicate, which was repeated four times.

tion, since these results are obtained in a cell line that contains endogenous *p23* (not shown). These findings suggest that *p23* is a limiting factor for ER signal transduction and therefore subsequent ER-mediated transcriptional enhancement.

## DISCUSSION

Using dosage suppression analysis in yeast cells to isolate factors involved in ER signal transduction, we have identified the yeast homologue of the human *p23* (*yhp23*) as a protein that, when overexpressed, results in a 10-fold increase in G400V ER transcriptional activation. In vivo estradiol-binding assays suggest that *yhp23* overexpression increases G400V ER transcriptional activity by increasing the number of estradiol-bound receptors. The effect of *yhp23* overexpression was not limited to G400V ER, as it also increases both ligand binding and transcriptional activation by wt ER. No effect of *yhp23* overexpression was observed on the constitutive activity of ER<sub>1-115</sub>, thereby demonstrating that *yhp23* does not affect AF-1 activity per se. We therefore conclude that *yhp23* is a member of the reconstituted steroid receptor signaling pathway in yeast cells, acting at the step of ligand binding by the receptor. This role is consistent with the currently proposed function of human *p23* in steroid receptor-aporeceptor complex formation.

By using a yeast strain deficient in *yhp23* expression (KO), analyses of wt ER signaling as a function of *yhp23*, wt ER, and estradiol concentrations were carried out. Our studies demonstrate that the magnitude of the effect of *yhp23* on wt ER transcriptional activation is inversely proportional to the concentration of both wt ER and estradiol. Thus, at low, subsaturating concentrations of estradiol, *yhp23* overexpression markedly increases wt ER transcriptional activation. In contrast, at saturating concentrations of estradiol, the effect of *yhp23* overexpression on wt ER transcriptional activation is comparatively small. Furthermore, the magnitude of the effect of *yhp23* on wt ER transcriptional activation is greater at low, rather than high, wt ER expression levels. Taken together, our findings indicate that the effect of *yhp23* on wt ER signaling varies depending on *yhp23*, wt ER, and estradiol concentrations.

Subcellular localization studies with a *yhp23*-GFP fusion protein indicate that *yhp23* is largely cytoplasmic in the ab-




FIG. 9. A model for p23-dependent and -independent ER signal transduction. A simplified version of the current model of aporeceptor complex formation as deduced from *in vitro* studies is indicated by the black arrows. Hsp90 refers to the Hsp90 dimer, 70 refers to Hsp70, 60 refers to p60, p23 refers to the mammalian p23 protein, ER refers to the estrogen receptor, and H refers to hormone. The immunophilins, which do not appear to be essential to aporeceptor complex formation but are isolated with the complex *in vivo* have been excluded from the model for simplicity. According to the model, p60, Hsp70 (and possibly Hsp40), and a dimer of Hsp90 preassociate to form the "foldosome" complex. The foldosome binds to the steroid-binding domain of the native receptor. Hsp70 and p60 are released from the complex in a process that requires ATP and a monovalent cation, while Hsp90 and the receptor undergo conformational changes, such that the receptor assumes a conformation with high affinity for steroid. This new complex (labeled "immature" in this figure) is inherently unstable and quickly dissociates unless p23 binds to Hsp90, thereby stabilizing the aporeceptor complex (labeled "mature" in this figure). Our data, however, suggests that a second, p23-independent pathway to ER ligand binding exists *in vivo*, occurring when ligand binds directly to the immature aporeceptor complex (open arrow), which is favored at high ER and/or estradiol concentrations. We suggest that the G400V ER mutation renders the receptor less capable of participating in the p23-independent pathway, thereby functionally uncoupling the p23-independent and -dependent pathways.

sence of ER expression. When coexpressed with either the mutant or wt ER, yhp23 colocalizes with the receptor to the nucleus in the absence of estradiol. This colocalization is reversed upon estradiol treatment, such that yhp23 is released into the cytoplasm. From these observations, we conclude that yhp23 is part of the ER aporeceptor complex in yeast cells and that the distribution of yhp23 within the cell is dynamic and affected both by ER expression and estradiol binding.

It has been proposed that the function of p23 in steroid receptor signaling is to promote, through its interaction with Hsp90, the maturation or stabilization of the aporeceptor complex (24, 30). This model, derived largely from *in vitro* experiments (45, 46), proposes that the heat shock proteins Hsp90, p60, Hsp70, and possibly Hsp40 (10) form a complex termed a "foldosome" (23), within which Hsp90 exists in a conformation incompatible with p23 binding (53) (Fig. 9). The foldosome binds to the free receptor, which exists in a conformation with low affinity for the ligand. In a process that requires ATP and monovalent cations, the Hsp90 component of the foldosome and the receptor undergo conformational changes (13), such that Hsp90 is now capable of binding p23 (53), and the receptor exhibits high-affinity steroid binding. p23 binding to Hsp90 appears to stabilize this immature aporeceptor complex *in vitro*. In the absence of p23, the Hsp90-receptor complex is inherently unstable and rapidly dissociates (13).

The ability of yhp23 to increase ER transcriptional activation might be expected if yhp23 is limiting for the formation of mature aporeceptor complexes. Although we cannot exclude the possibility that yhp23 overexpression increases the ratio of yhp23 binding to each molecule of ER, this idea runs contrary to the current model of p23 function. Increasing the concen-

tration of yhp23, therefore, would be expected to result in a greater number of mature ER aporeceptor complexes in the cell. As a result, the total estradiol binding will increase, which is consistent with our *in vivo* estradiol binding assays (Fig. 3). Thus, overexpression of yhp23, by increasing the number of mature aporeceptor complexes, will manifest itself as an increase in transcriptional activation by ER at a given hormone concentration (Fig. 2 and 4). Thus, our *in vivo* findings are consistent with the current model of p23 function as derived from *in vitro* experiments.

Our results indicating that wt ER activity is detectable in the absence of yhp23 (Fig. 4), however, suggest that in addition to the p23-dependent pathway, there must also exist a p23-independent pathway leading to estradiol binding and signaling by the ER. We propose that p23-independent activation of the ER *in vivo* occurs through estradiol binding directly to the immature (p23-deficient) aporeceptor complex (Fig. 9). This hypothesis is consistent with *in vitro* observations that in the absence of p23, the foldosome proteins Hsp90, Hsp70, and p60 are sufficient to induce the hormone-binding conformation of steroid receptors (13). We therefore propose that estradiol binding by the ER is a composite of both the p23-independent and p23-dependent pathways. The relative contribution of each pathway to ER activation is dependent upon the concentration of p23, ER, and estradiol (see below).

One prediction of our model is that yhp23 becomes less relevant to ER activation as the ratio of immature to mature aporeceptor complexes increases. The ratio of the two types of aporeceptor complexes is, in turn, a reflection of both ER and yhp23 concentrations. Increasing ER expression when p23 levels are constant results in a greater number of the immature aporeceptor complexes, which favors hormone binding through the p23-independent pathway. Conversely, increasing yhp23 levels facilitates the formation of mature aporeceptor complexes and therefore the p23-dependent pathway. This model of ER signal transduction is consistent with our *in vivo* findings that indicate that the magnitude of the effect of yhp23 on ER transcriptional activation is inversely proportional to the concentration of ER (Fig. 4D).

The proposed model further envisions that the concentration of estradiol also affects the relative contribution of the p23-dependent and p23-independent steroid binding pathways. As suggested by Fig. 9, free steroid can be considered to be competing with yhp23 for binding to the immature aporeceptor complex. As a result, the p23-independent pathway becomes more prominent as estradiol concentrations rise or, conversely, as yhp23 levels fall. Consistent with this notion, our data demonstrate that the magnitude of yhp23's effect on ER signaling is greatest at low subsaturating, rather than high saturating, estradiol concentrations (Fig. 4E). Thus, our model predicts that the balance among yhp23, ER, and estradiol, ultimately determines the relative contributions of the p23-dependent and p23-independent pathways to ER signal transduction.

Our model also provides insight into the observation that yhp23 overexpression induces G400V ER activity to a greater extent than that observed for wt ER (Fig. 2). We suggest that by altering the steroid-binding domain conformation, the G400V mutation largely eliminates the p23-independent pathway. G400V ER is temperature sensitive, relative to the wt ER, for estradiol binding *in vitro*, displaying reduced estradiol binding at 25°C but not at 4°C (54). This suggests that the G400V ER mutation destabilizes the conformation of the steroid-binding domain, such that the receptor is unable to bind steroid with high affinity at 25°C. This mutation does not inhibit G400V ER's interaction with the aporeceptor complex since G400V ER has been reported to be complexed with Hsp90 (1)

and since our subcellular localization studies suggest that G400V ER associates with yhp23 as efficiently as does wt ER. We therefore propose that the G400V mutation, by altering the structure of the steroid-binding domain, largely inhibits estradiol binding to the transient, immature aporeceptor complex, thereby diminishing estradiol binding through the p23-independent pathway. As a result, yhp23 competes more effectively with estradiol for binding to the complex, favoring the p23-dependent estradiol-binding pathway. The stability gained through yhp23 binding to the Hsp90-chaperone machinery, in turn, facilitates steroid binding by G400V ER.

It has been suggested by others that wt ER does not stably interact with Hsp90. This conclusion is based, in part, on studies with a VP16-Gal-ER<sub>LBD</sub> fusion protein (1, 37). Although these constructs continue to exhibit ligand-dependent activation, association of this construct with Hsp90 could not be demonstrated. While there are a number of possible reasons for this discrepancy, we feel that the most probable explanation is a difference in the inherent characteristics of the wt and fusion proteins (1). In addition, there are several reports that support a role for Hsp90 in the process of ligand binding by ER. (i) ER has been isolated with members of the aporeceptor complex from MCF-7 cells (52) and bovine uterus (49). (ii) Hsp90 has been demonstrated to colocalize with ER in the nucleus (38). (iii) ER function has been found to be affected by mutant Hsp90 molecules (44). (iv) ER function is also affected by the Hsp90-specific inhibitor geldanamycin (51). Although these studies do not exclude the possibility of additional transcriptional repressors of wt ER, these findings, along with our results, strongly support a role for the components of the Hsp90-based chaperone complex in ER signal transduction.

Elegant genetic studies of yhp23 function in yeast cells by Bohlen (2) and Fang et al. (16) demonstrate that yhp23 associates with Hsp90 and is a part of the GR aporeceptor complex in yeast cells. In contrast to our findings with ER, analysis of androgen receptor (AR) signaling in yeast cells suggests that it is largely p23 independent. This may reflect inherent differences in the mechanism of signal transduction employed by the receptors. Alternatively, we would suggest that, although the analysis of AR signaling was performed under a range of steroid concentrations, the levels of AR expression used may have favored the p23-independent pathway. It would be interesting to reevaluate AR signaling as a function of yhp23 at both low AR and testosterone concentrations, conditions that would favor the p23-dependent pathway.

The partial complementation of human p23 in yeast cells lacking yhp23 strongly suggests that yhp23 functions as the p23 homologue with respect to ER signaling (Fig. 7). Although the yeast and human p23 proteins have regions of identity, significant sequence differences between the proteins also exist (2). We speculate that this reflects species-specific differences in p23-Hsp90 association and might therefore explain the inability of human p23 to fully complement the loss of yhp23 function. It would be interesting to examine whether yeast cells expressing human Hsp90 (44) and p23 increase ER activity to the same extent as their yeast counterparts.

Finally, our studies also provide insight into the possible mechanisms by which the ER communicates with other signaling pathways. Unexpectedly, a significant increase in estradiol-independent activation of ER was observed as a result of yhp23 overexpression (Fig. 4F). This estradiol-independent activation of wt ER was also observed upon p23 overexpression in MCF-7 cells (Fig. 8). Previous studies have proposed that estradiol-independent transcriptional activation by wt ER results, in part, from ER phosphorylation through an epidermal growth factor-dependent pathway (4, 27). Thus, the most di-

rect interpretation of our data suggests that maintenance of ER within the aporeceptor complex facilitates (but is not essential to) estradiol-independent activity, perhaps by maintaining ER in a conformation amenable to phosphorylation.

Besides ER, several other signaling molecules (including c-Src and c-Raf) are dependent upon chaperone complexes for their function (45). Yeast cells deficient in the DnaJ homologue YDJ1, for instance, display both altered steroid receptor and Src kinase activity (31). Thus, molecular chaperones link diverse signaling pathways. Additional insight into the mechanism of this cross talk comes from our subcellular localization studies that reveal a striking colocalization of ER and yhp23 within the nucleus. Estradiol treatment was shown to liberate yhp23 (and presumably other chaperone proteins) from the nucleus, allowing it to redistribute throughout the cytoplasm, where it can potentially interact with other signaling proteins. Although our colocalization studies were carried out under conditions of overexpression, we speculate that estradiol activation of ER may, through the release of chaperone components, modulate the activity of a variety of chaperone-dependent pathways. In light of p23's role in stabilizing chaperone complexes, it is likely to play a key regulatory role in any such "chaperone signaling."

In conclusion, we have provided evidence that yhp23 is a member of the ER signaling pathway and a positive regulator of ER function. We also suggest that at high ER and/or estradiol concentrations, conditions often present in the yeast system or during transient overexpression of ER in cultured mammalian cells, ER signaling occurs largely through a p23-independent pathway. Under low physiological concentrations of ER and estradiol, p23 is likely to be an important contributor to ER signaling. Our results also indicate that alterations in the level or subcellular distribution of p23 are potential mechanisms for modulating estradiol-dependent and -independent ER transcriptional activation. We are currently examining whether the p23 levels, the subcellular distribution, or the modification state fluctuates between normal and tumor cells, during cellular proliferation, during differentiation, or upon growth factor treatment. As aporeceptor complex formation is also believed to be important for ligand binding by GR, PR, and AR, p23 likely plays an important role in these pathways as well.

#### ACKNOWLEDGMENTS

We thank S. Bohlen and D. Toft for the yeast p23 deletion strain and human p23 cDNA, respectively; B. Freeman and K. Yamamoto for generously providing the antiserum against yeast p23 protein; and M. Stallcup and P. Kushner for the GRP1 and ER expression vectors, respectively. We also thank I. Rogatsky, J. Trowbridge, A. Hittelman, and A. Caplan for critically reading the manuscript.

This work was supported by the Army Breast Cancer Research Fund grants DAMD17-94-4454, DAMD17-96-1-6032 (to M.J.G.), and DAMD-17-98-1-8134 and NIH Training Grant 2T32GM07308 from the National Institute of General Medical Sciences (to R.K.) and the Irma T. Hirsch Charitable Trust.

#### REFERENCES

1. Aumais, J. P., H. S. Lee, R. Lin, and J. H. White. 1997. Selective interaction of hsp90 with an estrogen receptor ligand-binding domain containing a point mutation. *J. Biol. Chem.* **272**:12229-12235.
2. Bohlen, S. P. 1998. Genetic and biochemical analysis of p23 and ansamycin antibiotics in the function of Hsp90-dependent signaling proteins. *Mol. Cell. Biol.* **18**:3330-3339.
3. Brzozowski, A. M., A. C. Pike, Z. Dauter, R. E. Hubbard, T. Bonn, O. Engstrom, L. Ohman, G. L. Greene, J. A. Gustafsson, and M. Carlquist. 1997. Molecular basis of agonism and antagonism in the oestrogen receptor. *Nature* **389**:753-758.
4. Bunone, G., P. A. Briand, R. J. Miksick, and D. Picard. 1996. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. *EMBO J.* **15**:2174-2183.

5. Caplan, A. J. 1997. Yeast molecular chaperones and the mechanism of steroid hormone action. *Trends Endocrinol. Metab.* 8:271-276.
6. Catelli, M. G., N. Binart, I. Jung-Testas, J. M. Renoir, E. E. Baulieu, J. R. Feramisco, and W. J. Welch. 1985. The common 90-kD protein component of non-transformed '8S' steroid receptors is a heat-shock protein. *EMBO J.* 4:3131-3135.
7. Chang, H. C., and S. Lindquist. 1994. Conservation of Hsp90 macromolecular complexes in *Saccharomyces cerevisiae*. *J. Biol. Chem.* 269:24983-24988.
8. Chang, H. C., D. F. Nathan, and S. Lindquist. 1997. In vivo analysis of the Hsp90 cochaperone Sti1 (p60). *Mol. Cell. Biol.* 17:318-325.
9. Cutolo, M., A. Sulli, B. Serio, S. Accardo, and A. T. Masi. 1995. Estrogens, the immune response and autoimmunity. *Clin. Exp. Rheumatol.* 13:217-226.
10. Dittmar, K. D., M. Banach, M. D. Galigiana, and W. B. Pratt. 1998. The role of DnaJ-like proteins in glucocorticoid receptor · hsp90 heterocomplex assembly by the reconstituted hsp90 · p60 · hsp70 foldosome complex. *J. Biol. Chem.* 273:7358-7366.
11. Dittmar, K. D., D. R. Demady, L. F. Stancato, P. Krishna, and W. B. Pratt. 1997. Folding of the glucocorticoid receptor by the heat shock protein (hsp) 90-based chaperone machinery. The role of p23 is to stabilize receptor · hsp90 heterocomplexes formed by hsp90 · p60 · hsp70. *J. Biol. Chem.* 272:21213-21220.
12. Dittmar, K. D., K. A. Hutchison, J. K. Owens-Grillo, and W. B. Pratt. 1996. Reconstitution of the steroid receptor · hsp90 heterocomplex assembly system of rabbit reticulocyte lysate. *J. Biol. Chem.* 271:12833-12839.
13. Dittmar, K. D., and W. B. Pratt. 1997. Folding of the glucocorticoid receptor by the reconstituted Hsp90-based chaperone machinery. The initial hsp90 · p60 · hsp70-dependent step is sufficient for creating the steroid binding conformation. *J. Biol. Chem.* 272:13047-13054.
14. Duina, A. A., H. C. Chang, J. A. Marsh, S. Lindquist, and R. F. Gaber. 1996. A cyclophilin function in Hsp90-dependent signal transduction. *Science* 274:1713-1715.
15. Elliston, J. F., S. E. Fawell, L. Klein-Hitpass, S. Y. Tsai, M.-J. Tsai, M. G. Parker, and B. W. O'Malley. 1990. Mechanism of estrogen receptor-dependent transcription in a cell-free system. *Mol. Cell. Biol.* 10:6607-6612.
16. Fang, Y., A. E. Fliss, J. Rao, and A. J. Caplan. 1998. *SBA1* encodes a yeast Hsp90 cochaperone that is homologous to vertebrate p23 proteins. *Mol. Cell. Biol.* 18:3727-3734.
17. Freeman, B. C., D. O. Toft, and R. I. Morimoto. 1996. Molecular chaperone machines: chaperone activities of the cyclophilin Cyp-40 and the steroid aporeceptor-associated protein p23. *Science* 274:1718-1720.
18. Garabedian, M. J., and K. M. Yamamoto. 1992. Genetic dissection of the signaling domain of a mammalian steroid receptor in yeast. *Mol. Biol. Cell* 3:1245-1257.
19. Ginsburg, G. S., and P. S. Douglas. 1996. Why cardiologists should be interested in estrogen. *Am. J. Cardiol.* 78:559-561.
20. Golemis, E. A., and R. Brent. 1997. Searching for interacting proteins with the two-hybrid system III, p. 43-72. *In* P. L. Bartel and S. Fields (ed.), *The yeast two-hybrid system*. Oxford University Press, New York, N.Y.
21. Hong, H., K. Kohli, M. J. Garabedian, and M. R. Stallcup. 1997. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of thyroid, retinoid, and vitamin D receptors. *Mol. Cell. Biol.* 17:2735-2744.
22. Hong, H., K. Kohli, A. Trivedi, D. L. Johnson, and M. R. Stallcup. 1996. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. *Proc. Natl. Acad. Sci. USA* 93:4948-4952.
23. Hutchison, K. A., K. D. Dittmar, and W. B. Pratt. 1994. All of the factors required for assembly of the glucocorticoid receptor into a functional heterocomplex with heat shock protein 90 are preassociated in a self-sufficient protein folding structure, a "foldosome." *J. Biol. Chem.* 269:27894-27899.
24. Hutchison, K. A., L. F. Stancato, J. K. Owens-Grillo, J. L. Johnson, P. Kirshna, D. O. Toft, and W. B. Pratt. 1995. The 23-kDa acidic protein in reticulocyte lysate is the weakly bound component of the hsp foldosome that is required for assembly of the glucocorticoid receptor into a functional heterocomplex with hsp90. *J. Biol. Chem.* 270:18841-18847.
25. Ing, N. H., J. M. Beckman, S. Y. Tsai, M. J. Tsai, and B. W. O'Malley. 1992. Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). *J. Biol. Chem.* 267:17617-17623.
26. Jacquier, A., P. Legrain, and B. Dujon. 1992. Sequence of a 10.7-kb segment of yeast chromosome XI identifies the APN1 and the BAF1 loci and reveals one tRNA gene and several new open reading frames including homologs to RAD2 and kinases. *Yeast* 8:121-132.
27. Joel, P. B., A. M. Traish, and D. A. Lannigan. 1998. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. *J. Biol. Chem.* 273:13317-13323.
28. Johnson, J. L., T. G. Beito, C. J. Krcso, and D. O. Toft. 1994. Characterization of a novel 23-kilodalton protein of unactive progesterone receptor complexes. *Mol. Cell. Biol.* 14:1956-1963.
29. Johnson, J. L., and D. O. Toft. 1995. Binding of p23 and hsp90 during assembly with the progesterone receptor. *Mol. Endocrinol.* 9:670-678.
30. Johnson, J. L., and D. O. Toft. 1994. A novel chaperone complex for steroid receptors involving heat shock proteins, immunophilins, and p23. *J. Biol. Chem.* 269:24989-24993.
31. Kimura, Y., I. Yahara, and S. Lindquist. 1995. The role of the protein chaperone YDJ1 in establishing Hsp90-mediated signal transduction pathways. *Science* 268:1362-1365.
32. King, W. J., and G. L. Greene. 1984. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. *Nature* 307:745-747.
33. Korach, K. S., J. F. Couse, S. W. Curtis, T. F. Washburn, J. Lindzey, K. S. Kimbro, E. M. Eddy, S. Migliaccio, S. M. Snedeker, D. B. Lubahn, D. W. Schomberg, and E. P. Smith. 1996. Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. *Recent Prog. Horm. Res.* 51:159-186.
34. Kralli, A., S. P. Bohen, and K. R. Yamamoto. 1995. LEM1, an ATP-binding-cassette transporter, selectively modulates the biological potency of steroid hormones. *Proc. Natl. Acad. Sci. USA* 92:4701-4705.
35. Kumar, V., and P. Chambon. 1988. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. *Cell* 55:145-156.
36. Kumar, V., S. Green, G. Stack, M. Berry, J. R. Jin, and P. Chambon. 1987. Functional domains of the human estrogen receptor. *Cell* 51:941-951.
37. Lee, H. S., J. Aumais, and J. H. White. 1996. Hormone-dependent transactivation by estrogen receptor chimera that do not interact with hsp90. Evidence for transcriptional repressors. *J. Biol. Chem.* 271:25727-25730.
38. Meng, X., J. Devin, W. P. Sullivan, D. Toft, E. E. Baulieu, and M. G. Catelli. 1996. Mutational analysis of Hsp90 alpha dimerization and subcellular localization: dimer disruption does not impede "in vivo" interaction with estrogen receptor. *J. Cell Sci.* 109:1677-1687.
39. Metzger, D., S. Ali, J. M. Bornert, and P. Chambon. 1995. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. *J. Biol. Chem.* 270:9535-9542.
40. Metzger, D., R. Losson, J. M. Bornert, Y. Lemoine, and P. Chambon. 1992. Promoter specificity of the two transcriptional activation functions of the human estrogen receptor in yeast. *Nucleic Acids Res.* 20:2813-2817.
41. Metzger, D., J. H. White, and P. Chambon. 1988. The human oestrogen receptor functions in yeast. *Nature* 334:31-36.
42. Nair, S. C., E. J. Toran, R. A. Rimerman, S. Hjermstad, T. E. Smithgall, and D. F. Smith. 1996. A pathway of multi-chaperone interactions common to diverse regulatory proteins: estrogen receptor, Fes tyrosine kinase, heat shock transcription factor Hsf1, and the aryl hydrocarbon receptor. *Cell Stress Chaperones* 1:237-250.
43. Onate, S. A., S. Y. Tsai, M. J. Tsai, and B. W. O'Malley. 1995. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. *Science* 270:1354-1357.
44. Picard, D., B. Khursheed, M. J. Garabedian, M. G. Fortin, S. Lindquist, and K. R. Yamamoto. 1990. Reduced levels of hsp90 compromise steroid receptor action in vivo. *Nature* 348:166-168.
45. Pratt, W. B. 1998. The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. *Proc. Soc. Exp. Biol. Med.* 217:420-434.
46. Pratt, W. B., and D. O. Toft. 1997. Steroid receptor interactions with heat shock protein and immunophilin chaperones. *Endocr. Rev.* 18:306-360.
47. Raisz, L. G. 1996. Estrogen and bone: new pieces to the puzzle. *Nat. Med.* 2:1077-1078.
48. Ratajczak, T., and A. Carrello. 1996. Cyclophilin 40 (Cyp-40), mapping of its hsp90 binding domain and evidence that FKBP52 competes with Cyp-40 for hsp90 binding. *J. Biol. Chem.* 271:2961-2965.
49. Ratajczak, T., A. Carrello, P. J. Mark, B. J. Warner, R. J. Simpson, R. L. Moritz, and A. K. Houelle. 1993. The cyclophilin component of the unactivated estrogen receptor contains a tetratricopeptide repeat domain and shares identity with p59 (FKBP59). *J. Biol. Chem.* 268:13187-13192.
50. Rogatsky, I., S. K. Logan, and M. J. Garabedian. 1998. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. *Proc. Natl. Acad. Sci. USA* 95:2050-2055.
51. Segnitz, B., and U. Gehring. 1997. The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. *J. Biol. Chem.* 272:18694-186701.
52. Segnitz, B., and U. Gehring. 1995. Subunit structure of the nonactivated human estrogen receptor. *Proc. Natl. Acad. Sci. USA* 92:2179-2183.
53. Sullivan, W., B. Stensgard, G. Caucutt, B. Bartha, N. McMahon, E. S. Alnemri, G. Litwack, and D. Toft. 1997. Nucleotides and two functional states of hsp90. *J. Biol. Chem.* 272:8007-8012.
54. Tora, L., A. Mullick, D. Metzger, M. Ponglikitmongkol, I. Park, and P. Chambon. 1989. The cloned human estrogen receptor contains a mutation which alters its hormone binding properties. *EMBO J.* 8:1981-1986.
55. Webster, N. J., S. Green, J. R. Jin, and P. Chambon. 1988. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. *Cell* 54:199-207.
56. Welshons, W. V., M. E. Lieberman, and J. Gorski. 1984. Nuclear localization of unoccupied oestrogen receptors. *Nature* 307:747-749.
57. Wickelgren, I. 1997. Estrogen stakes claim to cognition. *Science* 276:675-678.
58. Yager, J. D., and J. G. Liehr. 1996. Molecular mechanisms of estrogen carcinogenesis. *Annu. Rev. Pharmacol. Toxicol.* 36:203-232.